JP2015524844A - 組織再生のためのエキソソームおよびマイクロリボ核酸 - Google Patents
組織再生のためのエキソソームおよびマイクロリボ核酸 Download PDFInfo
- Publication number
- JP2015524844A JP2015524844A JP2015527540A JP2015527540A JP2015524844A JP 2015524844 A JP2015524844 A JP 2015524844A JP 2015527540 A JP2015527540 A JP 2015527540A JP 2015527540 A JP2015527540 A JP 2015527540A JP 2015524844 A JP2015524844 A JP 2015524844A
- Authority
- JP
- Japan
- Prior art keywords
- mir
- cells
- tissue
- exosomes
- exosome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 395
- 230000017423 tissue regeneration Effects 0.000 title description 31
- 239000002253 acid Substances 0.000 title description 2
- 150000007513 acids Chemical class 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract description 248
- 210000001519 tissue Anatomy 0.000 claims abstract description 156
- 238000000034 method Methods 0.000 claims abstract description 104
- 230000001172 regenerating effect Effects 0.000 claims abstract description 51
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 49
- 108700011259 MicroRNAs Proteins 0.000 claims abstract description 48
- 230000014509 gene expression Effects 0.000 claims abstract description 45
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 45
- 239000000203 mixture Substances 0.000 claims abstract description 40
- 230000035899 viability Effects 0.000 claims abstract description 25
- 239000002679 microRNA Substances 0.000 claims description 125
- 230000006378 damage Effects 0.000 claims description 46
- 108091032320 miR-146 stem-loop Proteins 0.000 claims description 38
- 108091024530 miR-146a stem-loop Proteins 0.000 claims description 38
- 238000011069 regeneration method Methods 0.000 claims description 38
- 230000008439 repair process Effects 0.000 claims description 36
- 208000014674 injury Diseases 0.000 claims description 35
- 210000005003 heart tissue Anatomy 0.000 claims description 34
- 230000006872 improvement Effects 0.000 claims description 31
- 208000027418 Wounds and injury Diseases 0.000 claims description 30
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 30
- 230000008929 regeneration Effects 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 28
- 208000010125 myocardial infarction Diseases 0.000 claims description 28
- 230000006870 function Effects 0.000 claims description 24
- 210000000130 stem cell Anatomy 0.000 claims description 24
- 241000282414 Homo sapiens Species 0.000 claims description 23
- 102100024550 Sphingomyelin phosphodiesterase 2 Human genes 0.000 claims description 19
- 108040005466 neutral sphingomyelin phosphodiesterase activity proteins Proteins 0.000 claims description 19
- 230000000747 cardiac effect Effects 0.000 claims description 18
- 230000033115 angiogenesis Effects 0.000 claims description 15
- 210000002216 heart Anatomy 0.000 claims description 15
- 230000002757 inflammatory effect Effects 0.000 claims description 15
- 108020004999 messenger RNA Proteins 0.000 claims description 15
- 108091048308 miR-210 stem-loop Proteins 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 claims description 12
- 230000037361 pathway Effects 0.000 claims description 12
- 230000028327 secretion Effects 0.000 claims description 12
- 230000003833 cell viability Effects 0.000 claims description 11
- 102000004157 Hydrolases Human genes 0.000 claims description 10
- 108090000604 Hydrolases Proteins 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 claims description 8
- 230000001154 acute effect Effects 0.000 claims description 8
- -1 miR27-a Proteins 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 230000004075 alteration Effects 0.000 claims description 7
- 230000006907 apoptotic process Effects 0.000 claims description 7
- 238000005119 centrifugation Methods 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 108091092825 miR-24 stem-loop Proteins 0.000 claims description 7
- 108091032978 miR-24-3 stem-loop Proteins 0.000 claims description 7
- 108091064025 miR-24-4 stem-loop Proteins 0.000 claims description 7
- 208000017667 Chronic Disease Diseases 0.000 claims description 6
- 108091046841 MiR-150 Proteins 0.000 claims description 6
- 108091033773 MiR-155 Proteins 0.000 claims description 6
- 108091062170 Mir-22 Proteins 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000004663 cell proliferation Effects 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 210000002064 heart cell Anatomy 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 108091061970 miR-26a stem-loop Proteins 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 230000001419 dependent effect Effects 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 108091007772 MIRLET7C Proteins 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 4
- 108091091807 let-7a stem-loop Proteins 0.000 claims description 4
- 108091057746 let-7a-4 stem-loop Proteins 0.000 claims description 4
- 108091028376 let-7a-5 stem-loop Proteins 0.000 claims description 4
- 108091024393 let-7a-6 stem-loop Proteins 0.000 claims description 4
- 108091091174 let-7a-7 stem-loop Proteins 0.000 claims description 4
- 108091007423 let-7b Proteins 0.000 claims description 4
- 108091024449 let-7e stem-loop Proteins 0.000 claims description 4
- 108091044227 let-7e-1 stem-loop Proteins 0.000 claims description 4
- 108091071181 let-7e-2 stem-loop Proteins 0.000 claims description 4
- 108091063986 let-7f stem-loop Proteins 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 108091044988 miR-125a stem-loop Proteins 0.000 claims description 4
- 108091091360 miR-125b stem-loop Proteins 0.000 claims description 4
- 108091050874 miR-19a stem-loop Proteins 0.000 claims description 4
- 108091086850 miR-19a-1 stem-loop Proteins 0.000 claims description 4
- 108091088468 miR-19a-2 stem-loop Proteins 0.000 claims description 4
- 108091037787 miR-19b stem-loop Proteins 0.000 claims description 4
- 108091070404 miR-27b stem-loop Proteins 0.000 claims description 4
- 108091037240 miR-423 stem-loop Proteins 0.000 claims description 4
- 230000010076 replication Effects 0.000 claims description 4
- 102100036093 Ectonucleotide pyrophosphatase/phosphodiesterase family member 7 Human genes 0.000 claims description 3
- 101000876377 Homo sapiens Ectonucleotide pyrophosphatase/phosphodiesterase family member 7 Proteins 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 230000003915 cell function Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000007717 exclusion Effects 0.000 claims description 3
- 230000002132 lysosomal effect Effects 0.000 claims description 3
- 108091060382 miR-140 stem-loop Proteins 0.000 claims description 3
- 108091030617 miR-140-1 stem-loop Proteins 0.000 claims description 3
- 108091023370 miR-140-2 stem-loop Proteins 0.000 claims description 3
- 210000001082 somatic cell Anatomy 0.000 claims description 3
- 238000013519 translation Methods 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 230000000754 repressing effect Effects 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 description 82
- 102000039446 nucleic acids Human genes 0.000 description 35
- 108020004707 nucleic acids Proteins 0.000 description 35
- 150000007523 nucleic acids Chemical class 0.000 description 35
- 230000000694 effects Effects 0.000 description 27
- 238000011282 treatment Methods 0.000 description 26
- 201000010099 disease Diseases 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 238000002560 therapeutic procedure Methods 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 15
- 238000002955 isolation Methods 0.000 description 15
- 206010061216 Infarction Diseases 0.000 description 13
- 230000009286 beneficial effect Effects 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 238000011534 incubation Methods 0.000 description 11
- 230000007574 infarction Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 231100000241 scar Toxicity 0.000 description 11
- 238000010186 staining Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 108091005461 Nucleic proteins Proteins 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 230000002107 myocardial effect Effects 0.000 description 8
- 230000000451 tissue damage Effects 0.000 description 8
- 231100000827 tissue damage Toxicity 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 7
- 230000030833 cell death Effects 0.000 description 7
- 238000002659 cell therapy Methods 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000004217 heart function Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 229960002378 oftasceine Drugs 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000003278 mimic effect Effects 0.000 description 5
- 239000002732 sphingomyelin phosphodiesterase inhibitor Substances 0.000 description 5
- 230000008733 trauma Effects 0.000 description 5
- 238000005199 ultracentrifugation Methods 0.000 description 5
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000008092 positive effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000002592 echocardiography Methods 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 108091059456 miR-92-1 stem-loop Proteins 0.000 description 3
- 108091084336 miR-92-2 stem-loop Proteins 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 210000002487 multivesicular body Anatomy 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000019624 protein content Nutrition 0.000 description 3
- 238000009163 protein therapy Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000013042 tunel staining Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 210000005167 vascular cell Anatomy 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 241000589876 Campylobacter Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 102000020018 Cystathionine gamma-Lyase Human genes 0.000 description 2
- 108010045283 Cystathionine gamma-lyase Proteins 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 102000013818 Fractalkine Human genes 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000013875 Heart injury Diseases 0.000 description 2
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 description 2
- 108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 description 2
- 208000034693 Laceration Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091093142 MiR-144 Proteins 0.000 description 2
- 108091026807 MiR-214 Proteins 0.000 description 2
- 108091028066 Mir-126 Proteins 0.000 description 2
- 108091027766 Mir-143 Proteins 0.000 description 2
- 108091028684 Mir-145 Proteins 0.000 description 2
- 102100023200 Mitochondrial fission process protein 1 Human genes 0.000 description 2
- 101710149340 Mitochondrial fission process protein 1 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 108091029810 SaRNA Proteins 0.000 description 2
- 108020004688 Small Nuclear RNA Proteins 0.000 description 2
- 102000039471 Small Nuclear RNA Human genes 0.000 description 2
- 102000008889 TNF receptor-associated factor TRAF Human genes 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003196 chaotropic effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000006744 dopaminergic deficit Effects 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000010370 hearing loss Effects 0.000 description 2
- 231100000888 hearing loss Toxicity 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 108091079012 miR-133a Proteins 0.000 description 2
- 108091024038 miR-133a stem-loop Proteins 0.000 description 2
- 108091062895 miR-144 stem-loop Proteins 0.000 description 2
- 108091091751 miR-17 stem-loop Proteins 0.000 description 2
- 108091069239 miR-17-2 stem-loop Proteins 0.000 description 2
- 108091031103 miR-181a stem-loop Proteins 0.000 description 2
- 108091046591 miR-181a-4 stem-loop Proteins 0.000 description 2
- 108091049627 miR-181a-5 stem-loop Proteins 0.000 description 2
- 108091063348 miR-193 stem-loop Proteins 0.000 description 2
- 108091036762 miR-193a stem-loop Proteins 0.000 description 2
- 108091073055 miR-193a-1 stem-loop Proteins 0.000 description 2
- 108091040345 miR-193a-2 stem-loop Proteins 0.000 description 2
- 108091025686 miR-199a stem-loop Proteins 0.000 description 2
- 108091092012 miR-199b stem-loop Proteins 0.000 description 2
- 108091062762 miR-21 stem-loop Proteins 0.000 description 2
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 2
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 2
- 108091007431 miR-29 Proteins 0.000 description 2
- 108091088477 miR-29a stem-loop Proteins 0.000 description 2
- 108091029716 miR-29a-1 stem-loop Proteins 0.000 description 2
- 108091092089 miR-29a-2 stem-loop Proteins 0.000 description 2
- 108091066559 miR-29a-3 stem-loop Proteins 0.000 description 2
- 108091007432 miR-29b Proteins 0.000 description 2
- 108091047189 miR-29c stem-loop Proteins 0.000 description 2
- 108091054490 miR-29c-2 stem-loop Proteins 0.000 description 2
- 108091063344 miR-30b stem-loop Proteins 0.000 description 2
- 108091074487 miR-34 stem-loop Proteins 0.000 description 2
- 108091092493 miR-34-1 stem-loop Proteins 0.000 description 2
- 108091059780 miR-34-2 stem-loop Proteins 0.000 description 2
- 108091039521 miR-363 stem-loop Proteins 0.000 description 2
- 108091056495 miR-363-1 stem-loop Proteins 0.000 description 2
- 108091025820 miR-363-2 stem-loop Proteins 0.000 description 2
- 108091027983 miR-378-1 stem-loop Proteins 0.000 description 2
- 108091089716 miR-378-2 stem-loop Proteins 0.000 description 2
- 108091056170 miR-499 stem-loop Proteins 0.000 description 2
- 108091050885 miR-499-1 stem-loop Proteins 0.000 description 2
- 108091038523 miR-499-2 stem-loop Proteins 0.000 description 2
- 108091034121 miR-92a stem-loop Proteins 0.000 description 2
- 108091041519 miR-92a-3 stem-loop Proteins 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940078677 sarna Drugs 0.000 description 2
- 230000009291 secondary effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102100034538 28S ribosomal protein S12, mitochondrial Human genes 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102100036849 C-C motif chemokine 24 Human genes 0.000 description 1
- 102100021933 C-C motif chemokine 25 Human genes 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 1
- 101710098272 C-X-C motif chemokine 11 Proteins 0.000 description 1
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010083647 Chemokine CCL24 Proteins 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 201000008228 Ependymoblastoma Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 206010014968 Ependymoma malignant Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102100020903 Ezrin Human genes 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000544583 Heterococcus <yellow-green algae> Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000639726 Homo sapiens 28S ribosomal protein S12, mitochondrial Proteins 0.000 description 1
- 101000897486 Homo sapiens C-C motif chemokine 25 Proteins 0.000 description 1
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 101000734646 Homo sapiens Programmed cell death protein 6 Proteins 0.000 description 1
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 101710173438 Late L2 mu core protein Proteins 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- 108010009254 Lysosomal-Associated Membrane Protein 1 Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 108091028080 MiR-132 Proteins 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 101000713102 Mus musculus C-C motif chemokine 1 Proteins 0.000 description 1
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 102100034785 Programmed cell death protein 6 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 108091007629 SLC50A1 Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 102100036280 Sugar transporter SWEET1 Human genes 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 1
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 1
- 108050000808 TNF receptor-associated factor TRAF Proteins 0.000 description 1
- 108091084544 TNF receptor-associated factor family Proteins 0.000 description 1
- 108700031126 Tetraspanins Proteins 0.000 description 1
- 102000043977 Tetraspanins Human genes 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000008065 acid anhydrides Chemical group 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000001008 atrial appendage Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Chemical group 0.000 description 1
- 229940030602 cardiac therapy drug Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000006721 cell death pathway Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000013003 endocytic recycling Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000001159 endocytotic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 108010055671 ezrin Proteins 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 108010019677 lymphotactin Proteins 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 108091035591 miR-23a stem-loop Proteins 0.000 description 1
- 108091092722 miR-23b stem-loop Proteins 0.000 description 1
- 108091031298 miR-23b-1 stem-loop Proteins 0.000 description 1
- 108091082339 miR-23b-2 stem-loop Proteins 0.000 description 1
- 108091055059 miR-30c stem-loop Proteins 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000024717 negative regulation of secretion Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 108091005706 peripheral membrane proteins Proteins 0.000 description 1
- 210000000680 phagosome Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1329—Cardiomyocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/28—Vascular endothelial cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
概して、1以上の比較的一般的な治療法の使用は、疾患の進行を止めるための試みにおける、損傷または罹患した組織の治療、すでに起きた損傷の逆行、さらなる損傷の予防および患者の健康状態の全体としての改善のために使用される。例えば、多数の病態は、総合的な方法論またはライフスタイルの変更(例えば、心血管疾患、糖尿病などのリスクを減少させるための食事の改善)により容易に治療可能である。多くの場合、より重度の病態は、より進んだ医療的介入を必要とする。薬剤療法または薬学的療法は、特定の疾患を患う患者を治療するために、日常的に施される。例えば、高血圧を患う患者は、血管の圧力および血液量を低下させ、それによって高血圧を治療するために、アンギオテンシン変換酵素(ACE)阻害剤の処方が可能である。さらに、癌患者は、多くの場合、癌性腫瘍の広がりを制限する、および/または癌性腫瘍を根絶するための試みにおいて、さまざまな抗癌化合物のパネルを処方される。外科的方法もまた、特定の疾患または傷害を治療するために用いることができる。場合により、埋め込み装置が、薬学的または外科的療法に加えて、またはそれらの代わりに使用される(例えば、心臓ペースメーカー)。近年では、追加の療法タイプ、例えば、遺伝子療法、タンパク質療法および細胞療法などが、非常に前途有望になってきている。
核酸はヌクレアーゼにより急速に分解されるので、核酸は、一般的に体内では遊離の核酸としては存在しない。ある型の核酸は、膜結合粒子を伴う。このような膜結合粒子は、大部分の細胞型から脱落し、細胞膜の断片から成り、DNA、RNA、mRNA、マイクロRNAおよびタンパク質を含有する。これらの粒子は多くの場合、それらが脱落された細胞の組成を反映する。エキソソームはこのような膜結合粒子の1つのタイプであり、通常、直径約15nmから約95nmの直径範囲であり、この直径範囲は、約15nmから約20nm、20nmから約30nm、約30nmから約40nm、約40nmから約50nm、約50nmから約60nm、約60nmから約70nm、約70nmから約80nm、約80nmから約90nm、約90nmから約95nmおよびこれらの重複範囲を含む。いくつかの実施形態において、エキソソームはより大きい(例えば、約140から約210nmの範囲であり、この範囲は、約140nmから約150nm、150nmから約160nm、160nmから約170nm、170nmから約180nm、180nmから約190nm、190nmから約200nm、200nmから約210nmおよびこれらの重複範囲を含む)。一部の実施形態において、もともとの細胞体から生み出されるエキソソームは、少なくとも1つの次元(例えば直径)において、元々の細胞体の100、200、300、400、500、600、700、800、900、1000、2000、5000、10,000分の1である。
本明細書において、細胞または組織が傷害、損傷、疾患あるいは機能および/または生存能力の喪失につながるいくつかの他の事象を受けた後で、細胞または組織の修復または再生に使用するための方法および組成物を提供する。組織の損傷が存在するかどうかに関わらず、損傷の予防および/または細胞間の核酸(またはタンパク質)の往復のための方法および組成物もまた提供する。
本明細書に開示の方法および組成物は、広範囲のタイプの損傷または疾患により影響を受けた細胞または組織の修復または再生に使用できる。本明細書に開示の組成物および方法は、遺伝による疾患、細胞または身体の機能障害の治療、正常もしくは異常な細胞の老化との戦い、耐性の誘導、免疫機能の調節に使用できる。さらに、細胞または組織は、外傷、例えば、鈍的衝撃、裂傷、血流の喪失などにより損傷され得る。細胞または組織は、副次的効果、例えば傷害後の炎症、感染症、(例えば、傷害または外傷の結果として遊離したプロテアーゼによる)自己消化によりさらに損傷され得る。本明細書に開示の方法および組成物はまた、ある実施形態において、急性事象の治療にも使用でき、該急性事象は、限定するものではないが、心筋梗塞、脊髄傷害、脳卒中および外傷性脳傷害を含む。いくつかの実施形態において、本明細書に開示の方法および組成物は、慢性疾患の治療に使用でき、該慢性疾患は、限定するものではないが、神経学的障害または神経変性障害(例えば、多発性硬化症、筋委縮性側索硬化症、熱中症、てんかん、アルツハイマー病、パーキンソン病、ハンチントン舞踏病、ドーパミン作動系障害(dopaminergic impairment)、AIDSなどの他の原因によりもたらされる痴呆、局所脳虚血を含む脳虚血、身体外傷、例えば、脳、脊髄、神経または網膜の挫滅または圧迫傷害を含む、CNSにおける挫滅または圧迫傷害、ならびに神経変性を生み出す任意の他の急性の傷害または損傷)、免疫不全、(例えば、骨髄の除去または移植の後の)骨髄の再増殖の促進、関節炎、自己免疫障害、炎症性腸疾患、癌、糖尿病、筋力低下(例えば、筋ジストロフィー、筋委縮性側索硬化症など)、進行性失明(例えば、黄斑変性)および進行性聴力喪失を含む。
いくつかの実施形態において、損傷または疾患により有害な影響を受けた組織の修復または再生に使用するための、エキソソームを含む組成物を提供する。いくつかの実施形態において、組成物は、エキソソームを含む、それからなる、または本質的にそれからなる。いくつかの実施形態において、エキソソームは、核酸、タンパク質またはこれらの組み合わせを含む。いくつかの実施形態において、エキソソーム内の核酸は、(ある実施形態はDNAを含むエキソソームを伴ったが)RNAの1以上の型を含む。RNAは、いくつかの実施形態において、メッセンジャーRNA、snRNA、saRNA、miRNAおよびこれらの組み合わせの1以上を含む。いくつかの実施形態において、miRNAは、miR−26a、miR27−a、let−7e、mir−19b、miR−125b、mir−27b、let−7a、miR−19a、let−7c、miR−140−3p、miR−125a−5p、miR−150、miR−155、mir−210、let−7b、miR−24、miR−423−5p、miR−22、let−7f、miR−146aおよびこれらの組み合わせの1以上を含む。いくつかの実施形態において、組成物は、合成マイクロRNAおよび薬学的に許容されるキャリアを含む、それからなる、または本質的にそれからなる。いくつかのこのような実施形態において、合成マイクロRNAはmiR146aを含む。いくつかの実施形態において、miRNAはpre−miRNA(例えば、成熟していない)であるが、一方で、一部の実施形態において、miRNAは成熟しており、さらに追加の実施形態において、pre−miRNAと成熟miRNAの組み合わせが使用される。
心臓組織の修復および再生のエリアの先行する研究は、心臓組織の修復および/または再生が直接および間接的因子の結果であることを実証していた。例えば、CDCが、再生された心臓組織のおよそ10%を占めていることが示されている。このような研究は、別の機序、例えば、間接的効果が働いていることを示唆している。上記のように、エキソソームおよびそれらの核酸内容物は、間接的機序による細胞または組織の修復および/または再生の提供に、少なくとも一部関与していると思われる。本実施例は、エキソソームおよびそれらの核酸内容物を特徴付けるために設計した。
in vitro実験に着手し、エキソソームの他の細胞型に対する再生促進および抗アポトーシス効果を評価した。エキソソームを、上記のようにCDCまたはNHDF細胞から単離した。エキソソームペレット分画の一部を、その後、培養した新生ラットの心室筋細胞(neonatal rat ventricular myocytes)(NRVM)と一緒に、チャンバースライドにおいておよそ7日間同時インキュベーションした。7日の終わりに、同時培養液を、増殖または細胞死(アポトーシスのマーカーにより測定)の指数変化に関して免疫組織化学により評価した。このプロトコルの概略図を図4に示す。図5Aは、TUNEL染色により測定した、NRVM細胞の死に関するデータを示す。NRVM細胞と、CDCから単離されたエキソソームとのインキュベーションは、対照細胞およびNHDF細胞由来のエキソソームと共にインキュベートされた細胞の両方と比較して、有意に低いアポトーシスの程度をもたらした(CDC:25.2±0.04%;NHDF:45.1±0.05%、p<0.01);対照:41.4±0.05%、n=4、p<0.05)。図5Bは、NRVM細胞とCDCから単離されたエキソソームとのインキュベーションが、対照細胞およびNHDF細胞由来のエキソソームと共にインキュベートされた細胞の両方と比較して、有意により多い細胞増殖活性(Ki67により測定して)をもたらしたことを示している(CDC:42.7±0.04%;NHDF22.5±0.04%;対照:9.1%±0.03%、n=4、p<0.001)。図5Cは、エキソソームなし、NHDF細胞由来のエキソソームと一緒、またはCDC由来のエキソソームと一緒にインキュベートしたNRCMにおけるTUNEL染色の共焦点蛍光顕微鏡分析を示す。図5Aのように、NRCMとエキソソームとのインキュベーションはアポトーシスを減少させ(TUNEL陽性染色が少ない)、CDC由来エキソソームは、NHDF由来のエキソソームよりもより有意な減少を提供した。図5Dは、Ki67染色の共焦点蛍光顕微鏡分析を示す。再度、図5Bに示すデータを総括すると、CDC由来エキソソームは、NRCMの増殖活性の増加をもたらす。まとめると、これらのデータは、細胞死を減少させ、増殖活性を増加させるそれらの能力に基づき、他の細胞型と比較して、CDCが組織の修復および/または再生に関連し特に有益であり得るエキソソームを提供することを示唆している。これらの効果は、いくつかの実施形態において、急性的に損傷された細胞または組織、または、たとえ慢性的に損傷または罹患した細胞または組織において実現された場合でも、損傷した細胞または組織の修復または再生を助ける。
損傷または罹患した領域における細胞または組織の増殖の増加および/または死の減少に加えて、血流の再建または維持は、細胞または組織の修復または再生において中枢的な役割を果たし得る。したがって、血管新生を促進するエキソソームの能力を評価した。ヒト臍帯静脈内皮細胞(HUVEC)を、さまざまな同時インキュベーション条件に供した。これらの条件を図6に表す。簡潔に言うと、HUVEC細胞を培養皿において成長因子低下MATRIGELで成長させた。細胞を、新生ラット心筋細胞培地(NRCM)、CDC由来エキソソーム添加MRCM、NHDF由来エキソソーム添加MRCM、血管細胞基礎培地(VCBM)または血管細胞成長培地、(VCGM)のいずれかにおいて成長させた。図7に示すように、VCGMは、VCBMと比較して強固な血管形成を誘導した(CDC:9393±689;NHDF:2813±494.5、対照、1097±116.1、n=3、p<0.05)。NRCM由来培地は、VCBMと同様の血管形成をもたらした(データ非掲載)。示したように、CDCに由来するエキソソームを添加した培地もまた、有意な血管形成を誘導したが、一方、NHDFに由来するエキソソームを添加した培地は、血管形成が少ないことが示された。さまざまな処理条件からもたらされた血管形成の代表的顕微鏡写真を図8A−8Eに示す。これらのデータは、細胞の増殖および細胞死の減少に対するプラスの効果に加えて、特定の細胞型に由来するエキソソームが血管形成を促進する能力を有することを実証し、この能力は、in vivoで新しい血管系を形成する能力の代表である。したがって、いくつかの実施形態において、エキソソーム(またはエキソソームの内容物、例えばmRNAまたはタンパク質)の、損傷または罹患した組織の領域への投与は、血管新生の増加をもたらす。これが順に、標的領域において細胞および組織の生存能力および/または機能を改善する能力を有する。
上記のin vitro実験結果を考慮して、in vivo実験を実施して、心筋梗塞後の心臓組織再生に対するエキソソーム投与の効果を決定した。急性心筋梗塞(MI)を、左冠動脈前下行枝中部の結紮によりおよそ3ヶ月齢のSCID/Beigeマウスに作り出し、エキソソーム調製物またはビヒクルを、2カ所の梗塞周囲部位に直接可視化の下で注入した。本明細書に開示のように、他の送達経路(例えば、冠動脈内、心筋内、IVなど)が、一部の実施形態において使用される。動物に、対照溶液(イスコフ改変ダルベッコ培地;IMDM)、間葉系幹細胞(MSC−XO)から単離されたエキソソーム、NHDF(NHDF−XO)から単離されたエキソソームまたはCDC(CDC−XO)から単離されたエキソソームのいずれかを与えた。注入後、各実験群の生存率を、時間と共に追跡した。加えて、MRI画像を、梗塞後1日、梗塞後14日および梗塞後30日に収集し、心臓組織の寸法を特徴付けた。図9は、生存実験の結果を要約する。顕著なことには、8匹のCDCエキソソーム注入マウスのうち7匹が30日間生存したことである。対照的に、10匹のNHDFエキソソーム注入マウスはわずか6匹しか30日間生存しなかった。7匹の対照マウスのうち6匹が30日間生存した。MSC−XOデータは非掲載である。全体の生存の改善に加えて、CDCから単離されたエキソソームの投与は、機能の改善をもたらした。これらのデータを図10に表し、これは、CDCに由来するエキソソームにより処置された群において、心筋梗塞後2週間および4週間の両方において有意に改善された左室駆出率(LVEF)を示す。CDCに由来するエキソソームによる処置の結果としてのLVEFの改善は、NHDFエキソソーム群(これは、対照またはMSC−XOにより処置された細胞と差がなかった)に見られる心機能の低下を考慮すると驚くべきである。2週間において、CDCエキソソーム群のLVEFは40.8±2.33%であった(NHDF群32.34±2.0%、MSC−XO群32.41±1.9%および対照群31.31±3.2%と比較;いずれもn=6、p<0.05)。4週間において、CDCエキソソーム群のLVEFは44.03±1.5%であった(NHDF群31.8±1.7%、MSC−XO群31.17±1.5%および対照群31.5±2.7%と比較;いずれもn=6、p<0.05)。
エキソソームが、罹患または損傷した組織の修復および/または再生を容易にできることを理解することだけが重要ではなく、エキソソームの効率的な収集のための工程を理解することもまた重要である。エキソソーム分泌に関与する機序を理解することおよびいくつかの実施形態が、エキソソーム単離の効率の最適化を可能にする。
上記のように、一部の実施形態において、エキソソーム由来産物(例えば、核酸もしくはタンパク質またはこれらの組み合わせ)は、損傷または罹患した細胞または組織に再生効果を提供するために投与することができる。ある実施形態において、DNAがエキソソームから単離できるが、一部の実施形態において、RNAがエキソソームから単離できる(DNAに加えて、またはその代わりに)。特定の型のRNA、例えばマイクロRNA(miRNAまたはmiR)などが、エキソソームにより担持されることが公知である。上記のように、miRNAは、多くの場合標的メッセンジャーRNA転写産物(mRNA)に対する相補配列に結合し、それによって、翻訳抑制、標的mRNAの変性および/または遺伝子サイレンシングをもたらすことによって、転写後レギュレーターとして機能する。エキソソームに含有されるmiRNAについてより理解を深めるために、miRNAのプロファイリング実験を実施した。エキソソームをCDCおよびNHDFの両方から上記のように調製し、全RNAを、確立された方法によってエキソソームから単離した。cDNAを全RNAから作製し、RT PCR反応において鋳型として使用して、miRNAのパネルの発現レベルを決定した。図18Aは、NHDF細胞と比較した、CDC中のさまざまなmiRNAの発現レベルを表す(データは、NHDF発現に関する倍数変化として表し、NHDF発現がX軸における「0」値である)。図のように、CDCおよび対照細胞の間で差次的発現を示すさまざまなmiRNAが存在する。一部の実施形態において、対照細胞を上回る発現の増加を示すmiRNAが、(例えば、このようなmiRNAを含有するエキソソームの投与、またはmiRNAの直接投与により)その後の組織再生に使用される候補である。特に、miR146aは、CDCにおいて250倍を超える発現増加を示す。図18Bは、CDCと比較してNHDF細胞において同等に発現するmiRNA(この実施形態において、同等は、発現の10倍未満の変化に設定した)、CDCにおいて有意に上方制御されるmiRNA(右)およびCDCにおいて有意に下方制御されるmiRNA(左)の一覧表を示す。しかし、一部の実施形態において、被験細胞型に依存して、他のmiRNAが発現の改変を示す。例えば、一部の実施形態において、対照細胞と比較して、発現の低下を示すmiRNAは、組織再生におけるその後の使用の候補である。miRNA発現が上方制御されるか、または下方制御されるかが、miRNAが、その後翻訳の抑制または翻訳のディスク阻止に関連する経路に関与するかどうかに関係し得る。
Claims (56)
- 損傷組織を有する個体において組織を再生する方法であって、
損傷組織を有する個体を同定するステップ、
複数のエキソソームを前記個体に投与するステップを含み、
前記エキソソームがヒト非胚性再生細胞から分泌され、
前記エキソソームが1以上のマイクロRNA断片を含み、
前記複数のエキソソームの投与後、前記1以上のマイクロRNA断片が該損傷組織において遺伝子発現を改変し、前記損傷組織の生存能力を改善し、前記個体において新しい組織の形成を容易にする、
方法。 - 該損傷組織が心臓組織を含む、請求項1に記載の方法。
- 該ヒト非胚性再生細胞が心筋球由来細胞(CDC)を含む、請求項1に記載の方法。
- 該ヒト非胚性再生細胞が心筋球を含む、請求項1に記載の方法。
- 前記1以上のマイクロRNA断片が、miR−26a、miR27−a、let−7e、mir−19b、miR−125b、mir−27b、let−7a、miR−19a、let−7c、miR−140−3p、miR−125a−5p、miR−150、miR−155、mir−210、let−7b、miR−24、miR−423−5p、miR−22、let−7f、miR−146aおよびこれらの組み合わせからなる群から選択される、請求項1に記載の方法。
- 前記1以上のマイクロRNA断片がmiR−146aを含む、請求項1に記載の方法。
- 前記1以上のマイクロRNA断片がmiR−210を含む、請求項1に記載の方法。
- 前記エキソソームが、前記ヒト非胚性再生細胞の遠心分離により得られる、請求項1に記載の方法。
- 前記エキソソームが、前記ヒト非胚性再生細胞のサイズ排除ろ過により得られる、請求項1に記載の方法。
- 該エキソソームが直径約20nmから約90nmである、請求項1に記載の方法。
- 前記複数のエキソソームの投与が前記組織の機能を改善する、請求項1に記載の方法。
- 該エキソソームが、翻訳の抑制および/またはmRNAの切断により遺伝子発現を改変する、請求項1に記載の方法。
- 該遺伝子発現の改変が、望ましくないタンパク質の阻害をもたらす、請求項1に記載の方法。
- 該遺伝子発現の改変が、所望のタンパク質の産生を、直接または間接的にもたらす、請求項1に記載の方法。
- 該遺伝子発現の改変が、1以上の炎症性物質の発現を減少させる、請求項1に記載の方法。
- 前記エキソソームが、血管新生を直接または間接的に刺激する、請求項1に記載の方法。
- 前記エキソソームが、細胞複製に直接または間接的に影響を与える、請求項1に記載の方法。
- 前記エキソソームが、細胞のアポトーシスを直接または間接的に阻害する、請求項1に記載の方法。
- 前記ヒト非胚性再生細胞を前記個体に投与するステップをさらに含む、請求項1から18のいずれか一項に記載の方法。
- 該ヒト非胚性再生細胞が、前記個体に対して自己由来である、請求項1から19のいずれか一項に記載の方法。
- 該ヒト非胚性再生細胞が、前記個体に対して同種異系である、請求項1から19のいずれか一項に記載の方法。
- 前記エキソソームが、該損傷組織の1以上のレシピエント細胞と融合する、請求項1から21のいずれか一項に記載の方法。
- 前記エキソソームが、該マイクロRNAを該損傷組織の1以上のレシピエント細胞内に放出し、それによって、該損傷組織の前記1以上の細胞において少なくとも1つの経路を改変する、請求項1から22のいずれか一項に記載の方法。
- 前記エキソソームが、該損傷組織の細胞を取り巻く環境を改変することによって、該損傷組織の細胞に対するそれらの影響力を発揮する、請求項1から23のいずれか一項に記載の方法。
- 該損傷組織の該細胞が健康な細胞である、請求項23または24に記載の方法。
- 該損傷組織の該細胞が損傷細胞である、請求項23または24に記載の方法。
- 前記エキソソームが合成的に作製される、請求項1から26のいずれか一項に記載の方法。
- 前記エキソソームが、前記組織の再生および/または機能改善を容易にする少なくとも1つのタンパク質をさらに含む、請求項1から27のいずれか一項に記載の方法。
- 前記エキソソームが、前記組織に局所的に送達される、請求項1から28のいずれか一項に記載の方法。
- 前記エキソソームが前記対象に全身的に送達される、請求項1から29のいずれか一項に記載の方法。
- 前記エキソソームが、心筋内経路により前記対象に送達される、請求項1から29のいずれか一項に記載の方法。
- 前記エキソソームが、冠動脈内経路により前記対象に送達される、請求項1から29のいずれか一項に記載の方法。
- 該損傷組織が、急性事象により修復、再生または機能改善を必要とする、請求項1から32のいずれか一項に記載の方法。
- 前記組織が心臓組織であり、前記急性事象が心筋梗塞を含む、請求項33に記載の方法。
- 前記エキソソームの投与が、梗塞を受けたエリアの心臓の壁厚の増加をもたらす、請求項34に記載の方法。
- 前記心臓組織が、慢性疾患により修復、再生または機能改善を必要とする、請求項1から32のいずれか一項に記載の方法。
- 前記損傷組織が、傷害、加齢に伴う変性、癌および感染症の1以上からもたらされる、請求項1から32のいずれか一項に記載の方法。
- 前記ヒト非胚性再生細胞が、修復または再生を必要とする同じ組織型由来である、請求項1に記載の方法。
- 前記ヒト非胚性再生細胞が、修復または再生を必要とする組織以外の組織型由来である、請求項1に記載の方法。
- 前記ヒト非胚性再生細胞が体細胞を含む、請求項1に記載の方法。
- 損傷または罹患した心臓組織の修復または再生のための組成物であって、
心臓幹細胞の集団から単離された複数のエキソソームを含み、
前記心臓幹細胞が心筋球由来細胞の集団を含み、
前記エキソソームが少なくとも1つのマイクロRNAを含み、
前記マイクロRNAがmiR−146a、miR−22、miR−24、およびmiR−26aからなる群から選択され、ならびに
損傷または罹患した心臓組織を有する対象に対する投与において、前記エキソソームが心臓細胞の生存能力、心臓細胞の増殖および心臓細胞の機能の1以上を増加させる、
組成物。 - 前記組成物が、複数の心臓幹細胞をさらに含む、請求項41に記載の組成物。
- 合成マイクロRNA−146aおよび薬学的に許容されるキャリアを含む、損傷または罹患した心臓組織の修復または再生のための組成物。
- 損傷組織を有する個体において組織を再生する方法であって、
損傷組織を有する個体を同定するステップ、
1以上のマイクロRNA断片またはこれらの誘導体を前記個体に投与するステップを含み、
前記1以上のマイクロRNA断片の投与後、前記1以上のマイクロRNA断片が、該損傷組織における遺伝子発現を改変し、前記損傷組織の生存能力を改善し、前記個体において新しい組織の形成を容易にする、
方法。 - 前記マイクロRNA断片またはこれらの誘導体が、miR−26a、miR27−a、let−7e、mir−19b、miR−125b、mir−27b、let−7a、miR−19a、let−7c、miR−140−3p、miR−125a−5p、miR−150、miR−155、mir−210、let−7b、miR−24、miR−423−5p、miR−22、let−7f、miR−146aおよびこれらの組み合わせからなる群から選択される、請求項44に記載の方法。
- 前記マイクロRNA断片またはこれらの誘導体が、合成的に作製される、請求項44または45に記載の方法。
- 該マイクロRNA断片またはこれらの誘導体が、1以上の内因性マイクロRNA分子を模倣する配列により合成される、請求項46に記載の方法。
- 該マイクロRNA断片またはこれらの誘導体が修飾されて、それらの安定性を強化する、請求項46に記載の方法。
- 前記投与が、前記1以上のマイクロRNA断片またはこれらの誘導体を含む複数の合成リポソームの投与を含む、請求項44から48のいずれか一項に記載の方法。
- エキソソームを作製する方法であって、
ヒト非胚性再生細胞の集団を得るステップ、
前記ヒト非胚性再生細胞の集団を培養するステップ、および
前記ヒト非胚性再生細胞の培養集団をヒドロラーゼ酵素に曝露して、細胞のエキソソーム分泌を誘導し、それによってエキソソームを作製するステップ、
を含む方法。 - 前記分泌されたエキソソームを回収するステップをさらに含む、請求項50に記載の方法。
- 前記ヒドロラーゼが、酵素のDNAse Iスーパーファミリーのメンバーを含む、請求項50または51に記載の方法。
- 前記ヒドロラーゼがスフィンゴミエリナーゼを含む、請求項50から52のいずれか一項に記載の方法。
- 前記スフィンゴミエリナーゼが、リソソーム酸性スフィンゴミエリナーゼ、分泌型亜鉛依存性酸性スフィンゴミエリナーゼ、中性スフィンゴミエリナーゼおよびアルカリ性スフィンゴミエリナーゼからなる群から選択される型である、請求項53に記載の方法。
- 前記中性スフィンゴミエリナーゼが、マグネシウム依存性中性スフィンゴミエリナーゼおよびマグネシウム非依存性中性スフィンゴミエリナーゼの1以上を含む、請求項54に記載の方法。
- 前記中性スフィンゴミエリナーゼが、中性スフィンゴミエリナーゼI型、中性スフィンゴミエリナーゼ2型および中性スフィンゴミエリナーゼ3型の1以上を含む、請求項54に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261682666P | 2012-08-13 | 2012-08-13 | |
US61/682,666 | 2012-08-13 | ||
PCT/US2013/054732 WO2014028493A2 (en) | 2012-08-13 | 2013-08-13 | Exosomes and micro-ribonucleic acids for tissue regeneration |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018209427A Division JP6726726B2 (ja) | 2012-08-13 | 2018-11-07 | 組織再生のためのエキソソームおよびマイクロリボ核酸 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015524844A true JP2015524844A (ja) | 2015-08-27 |
JP2015524844A5 JP2015524844A5 (ja) | 2016-09-29 |
JP6433896B2 JP6433896B2 (ja) | 2018-12-05 |
Family
ID=50101594
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015527540A Active JP6433896B2 (ja) | 2012-08-13 | 2013-08-13 | 組織再生のためのエキソソームおよびマイクロリボ核酸 |
JP2018209427A Active JP6726726B2 (ja) | 2012-08-13 | 2018-11-07 | 組織再生のためのエキソソームおよびマイクロリボ核酸 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018209427A Active JP6726726B2 (ja) | 2012-08-13 | 2018-11-07 | 組織再生のためのエキソソームおよびマイクロリボ核酸 |
Country Status (6)
Country | Link |
---|---|
US (4) | US9828603B2 (ja) |
EP (2) | EP2882445B1 (ja) |
JP (2) | JP6433896B2 (ja) |
AU (1) | AU2013302799B2 (ja) |
CA (1) | CA2881394A1 (ja) |
WO (1) | WO2014028493A2 (ja) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018199231A1 (ja) * | 2017-04-28 | 2018-11-01 | 一丸ファルコス株式会社 | プラセンタ抽出物 |
JP2019508461A (ja) * | 2016-03-14 | 2019-03-28 | カプリコール,インコーポレイテッド | 眼炎症および目の化学的損傷を細胞外小胞で処置する方法 |
JP2019513414A (ja) * | 2016-03-24 | 2019-05-30 | ステムラボ,エスエイ | 組織修復のための臍帯血由来エキソソームの使用 |
JP2019514927A (ja) * | 2016-04-29 | 2019-06-06 | アドヴァンスド リジェン メディカル テクノロジーズ,エルエルシー | マイクロrna組成物並びにその作製及び使用方法 |
JP2019526388A (ja) * | 2016-09-09 | 2019-09-19 | アシスタンス パブリック−オピトークス ド パリ(エーピーエイチピー) | 治療用バイオマテリアル |
JP2020518564A (ja) * | 2017-05-05 | 2020-06-25 | カプリコール,インコーポレイテッド | 細胞外小胞を用いた全身移植片対宿主病を治療する方法 |
JP2020529477A (ja) * | 2017-08-04 | 2020-10-08 | シーダーズ—シナイ メディカル センター | がんの治療及び防止のためのカルディオスフィア由来細胞及びその細胞外小胞 |
WO2020209304A1 (ja) * | 2019-04-09 | 2020-10-15 | 孝広 落谷 | 線維化、炎症、及び/又は老化疾患に対する治療薬 |
US11286463B2 (en) | 2012-03-08 | 2022-03-29 | Advanced ReGen Medical Technologies, LLC | Reprogramming of aged adult stem cells |
WO2022202930A1 (ja) * | 2021-03-23 | 2022-09-29 | 国立大学法人京都大学 | 組成物および医薬組成物 |
JP2022180432A (ja) * | 2016-09-09 | 2022-12-06 | コーネル・ユニバーシティー | 硝子体小胞中の核酸、タンパク質及び小分子の送達方法 |
US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
US11759482B2 (en) | 2017-04-19 | 2023-09-19 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
EP2882445B1 (en) * | 2012-08-13 | 2019-04-24 | Cedars-Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
US10500231B2 (en) | 2013-03-13 | 2019-12-10 | University Of Miami | Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids |
WO2014197421A1 (en) | 2013-06-05 | 2014-12-11 | Biotime, Inc. | Compositions and methods for induced tissue regeneration in mammalian species |
JP6353073B2 (ja) | 2013-12-20 | 2018-07-04 | アドヴァンスド リジェン メディカル テクノロジーズ,エルエルシー | 細胞回復のための組成物並びにその作製及び使用方法 |
US10772911B2 (en) | 2013-12-20 | 2020-09-15 | Advanced ReGen Medical Technologies, LLC | Cell free compositions for cellular restoration and methods of making and using same |
US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
EP3122333A4 (en) * | 2014-03-24 | 2017-11-29 | Advanced Regen Medical Technologies, LLC | Cell free compositions for cellular restoration and methods of making and using same |
EP3132044B1 (en) | 2014-04-18 | 2020-04-08 | University of Massachusetts | Exosomal loading using hydrophobically modified oligonucleotides |
US10568945B2 (en) | 2014-04-25 | 2020-02-25 | University Of Cincinnati | Compositions and methods for inducing liver regeneration by administering hepatocyte-derived exosomes |
US20150328263A1 (en) * | 2014-05-14 | 2015-11-19 | University Of Maryland, Baltimore | Cardiac stem cells for cardiac repair |
RU2620069C2 (ru) * | 2014-06-26 | 2017-05-22 | Аоварт Гмбх | Вещество и способ модуляции пролиферации и дифференцировки регуляторных, стволовых и других соматических клеток |
US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
AU2015327812B2 (en) * | 2014-10-03 | 2021-04-15 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
EP3204117A4 (en) * | 2014-10-06 | 2018-05-09 | Cedars-Sinai Medical Center | Polarization of macrophages to a healing phenotype by cardiosphere-derived cells and by the exosomes secreted by such cells |
AU2015330855A1 (en) | 2014-10-09 | 2017-04-27 | Celularity Inc. | Placenta-derived adherent cell exosomes and uses thereof |
JP2017537630A (ja) * | 2014-12-03 | 2017-12-21 | カプリコール,インコーポレイテッド | 低酸素培養条件におけるエクソソームの生成方法 |
WO2016196822A1 (en) * | 2015-06-02 | 2016-12-08 | Cedars-Sinai Medical Center | Urodele exosomes as therapeutic agents |
SG11201804405PA (en) * | 2015-11-25 | 2018-06-28 | Univ Colorado Regents | Use of microrna-146a and nanoceria conjugate to improve wound healing and promote tissue regeneration |
WO2017123662A1 (en) | 2016-01-11 | 2017-07-20 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
JP7120628B2 (ja) * | 2016-03-22 | 2022-08-17 | カプリコール,インコーポレイテッド | 細胞外小胞による放射線誘発性皮膚炎を予防するまたは治療する方法 |
US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
CN107557464B (zh) * | 2016-07-02 | 2021-06-04 | 上海市公共卫生临床中心 | 用于干扰素治疗慢性乙型肝炎早期病毒学反应的预测模型及检测试剂盒 |
EP3352769A1 (en) * | 2016-08-17 | 2018-08-01 | Orthogen AG | Anti-ageing pharmaceutical preparation |
EP3500244A4 (en) * | 2016-08-22 | 2020-05-13 | Codiak BioSciences, Inc. | METHOD FOR SUPPRESSING THE DELIVERY OF EXOSOMES TO LIVER AND SPLEEN |
WO2018057542A1 (en) | 2016-09-20 | 2018-03-29 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
IT201700035315A1 (it) * | 2017-03-30 | 2018-09-30 | Foundation For Cardiological Res And Education Fcre | Dispositivo e metodo di produzione e purificazione di esosomi |
WO2018177583A1 (en) * | 2017-03-30 | 2018-10-04 | Lugano Technology Transfer (LTT) SA | Device and method for producing and purifying exosomes |
US20200087625A1 (en) * | 2017-03-30 | 2020-03-19 | Dennis A. Carson | Methods for isolating, expanding and administering cancer specific cd8+ t cells |
US20200113943A1 (en) * | 2017-06-05 | 2020-04-16 | The Regents Of The University Of California | Methods for enhanced production and isolation of cell-derived vesicles and treatment of inflammation and neurological damage |
EP3675871A4 (en) * | 2017-08-31 | 2021-10-27 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | COMPOSITIONS AND METHODS OF TREATMENT OF FIBROTIC DISEASES |
WO2019055337A1 (en) * | 2017-09-13 | 2019-03-21 | Children's Hospital Medical Center | ROLE OF EXOSOMES, EXTRACELLULAR VESICLES IN THE REGULATION OF METABOLIC HOMÉOSTASIE |
US10717981B2 (en) | 2018-01-18 | 2020-07-21 | Advanced ReGen Medical Technologies, LLC | Therapeutic compositions and methods of making and using the same |
WO2020069313A2 (en) * | 2018-09-28 | 2020-04-02 | Henry Ford Health System | Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke |
US20210369789A1 (en) * | 2018-10-04 | 2021-12-02 | Exogenus Therapeutics, Sa | Compositions comprising small extracellular vesicles derived from umbilical cord blood mononuclear cells with anti-inflammatory and immunomodulatory properties and process for obtaining them |
MX2021009485A (es) * | 2019-02-07 | 2021-09-23 | Direct Biologics Llc | Metodo para el tratamiento de la osteoartritis con una combinacion de exosomas de celulas madre mesenquimales, celulas madre mesenquimales sinoviales, y soportes. |
WO2020190672A1 (en) * | 2019-03-15 | 2020-09-24 | North Carolina State University | Cardiomyocyte-derived exosomes inducing regeneration of damaged heart tissue |
TW202122572A (zh) | 2019-08-09 | 2021-06-16 | 日商宇部興產股份有限公司 | 胞外體的產生方法 |
CN114929243A (zh) * | 2019-11-29 | 2022-08-19 | 诺瓦迪普生物科学股份公司 | 基于miRNA的药物组合物及其用于预防和治疗组织病变的用途 |
US20210186831A1 (en) * | 2019-12-19 | 2021-06-24 | North Carolina State University | Therapeutic compositions and methods using exosomes derived from human dermal fibroblasts |
WO2021151029A1 (en) * | 2020-01-22 | 2021-07-29 | Agex Therapeutics, Inc. | Therapeutic exosomes and method of producing them |
WO2021178514A1 (en) * | 2020-03-04 | 2021-09-10 | Cedars-Sinai Medical Center | Cardiosphere-derived cells, exosomes derived therefrom, and methods of using same to treat volumetric muscle loss |
WO2022109446A1 (en) * | 2020-11-23 | 2022-05-27 | The Government Of The United States As Represented By The Secretary Of The Army | Extracellular vesicles derived from cardiosphere-derived cells as anti-shock therapeutics |
CN112852713B (zh) * | 2021-02-07 | 2023-08-18 | 广州四叶草健康科技有限公司 | 一种人体皮肤成纤维细胞外泌体制备分离方法 |
WO2023154729A2 (en) * | 2022-02-08 | 2023-08-17 | Temple University-Of The Commonwealth System Of Higher Education | Compositions and methods for cardiac tissue regeneration |
WO2023168153A1 (en) * | 2022-03-03 | 2023-09-07 | Fibrobiologics, Inc. | Therapeutic use of fibroblasts to stimulate regeneration and repair of atrophied spleen |
Family Cites Families (350)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3470876A (en) | 1966-09-28 | 1969-10-07 | John Barchilon | Dirigible catheter |
US4106488A (en) | 1974-08-20 | 1978-08-15 | Robert Thomas Gordon | Cancer treatment method |
US3964468A (en) | 1975-05-30 | 1976-06-22 | The Board Of Trustees Of Leland Stanford Junior University | Bioptome |
US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
GB8711614D0 (en) | 1987-05-16 | 1987-06-24 | Medical Res Council | Proteins |
US4960134A (en) | 1988-11-18 | 1990-10-02 | Webster Wilton W Jr | Steerable catheter |
US5175004A (en) | 1988-12-27 | 1992-12-29 | Matsumura Kenneth N | Propagatable, new combinant cells for cellular replacement therapy |
US4921482A (en) | 1989-01-09 | 1990-05-01 | Hammerslag Julius G | Steerable angioplasty device |
US5052402A (en) | 1989-01-31 | 1991-10-01 | C.R. Bard, Inc. | Disposable biopsy forceps |
US5104787A (en) | 1990-03-05 | 1992-04-14 | Lindstrom Richard L | Method for apparatus for a defined serumfree medical solution useful for corneal preservation |
US6326198B1 (en) | 1990-06-14 | 2001-12-04 | Regents Of The University Of Michigan | Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells |
US5401629A (en) | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
ATE123957T1 (de) | 1990-12-07 | 1995-07-15 | Ruesch Willy Ag | Medizinisches instrument mit lenkbarer spitze. |
AU660444B2 (en) | 1991-02-15 | 1995-06-29 | Ingemar H. Lundquist | Torquable catheter and method |
US5329923A (en) | 1991-02-15 | 1994-07-19 | Lundquist Ingemar H | Torquable catheter |
US5315996A (en) | 1991-02-15 | 1994-05-31 | Lundquist Ingemar H | Torquable catheter and method |
US5228441A (en) | 1991-02-15 | 1993-07-20 | Lundquist Ingemar H | Torquable catheter and method |
US5454787A (en) | 1991-02-15 | 1995-10-03 | Lundquist; Ingemar H. | Torquable tubular assembly and torquable catheter utilizing the same |
US5981165A (en) | 1991-07-08 | 1999-11-09 | Neurospheres Holdings Ltd. | In vitro induction of dopaminergic cells |
US5287857A (en) | 1992-06-22 | 1994-02-22 | David Mann | Apparatus and method for obtaining an arterial biopsy |
US5243167A (en) | 1992-09-16 | 1993-09-07 | Ingemar H. Lundquist | Apparatus and method for manufacturing a slotted torque tube |
US5334145A (en) | 1992-09-16 | 1994-08-02 | Lundquist Ingemar H | Torquable catheter |
US5383852A (en) | 1992-12-04 | 1995-01-24 | C. R. Bard, Inc. | Catheter with independent proximal and distal control |
US5368564A (en) | 1992-12-23 | 1994-11-29 | Angeion Corporation | Steerable catheter |
US5492825A (en) | 1993-08-06 | 1996-02-20 | The Regents Of The University Of California | Mammalian inward rectifier potassium channel cDNA, IRK1, corresponding vectors, and transformed cells |
US5616568A (en) | 1993-11-30 | 1997-04-01 | The Research Foundation Of State University Of New York | Functionalized derivatives of hyaluronic acid |
US5454827A (en) | 1994-05-24 | 1995-10-03 | Aust; Gilbert M. | Surgical instrument |
US5840502A (en) | 1994-08-31 | 1998-11-24 | Activated Cell Therapy, Inc. | Methods for enriching specific cell-types by density gradient centrifugation |
US5702905A (en) | 1994-09-28 | 1997-12-30 | Spectral Diagnostics | Monoclonal antibody to human ventricular myosin light chains |
US5872109A (en) | 1995-02-07 | 1999-02-16 | Shiseido Company, Ltd. | Anti-inflammatory agent |
US5551427A (en) | 1995-02-13 | 1996-09-03 | Altman; Peter A. | Implantable device for the effective elimination of cardiac arrhythmogenic sites |
US5715832A (en) | 1995-02-28 | 1998-02-10 | Boston Scientific Corporation | Deflectable biopsy catheter |
US5925567A (en) | 1995-05-19 | 1999-07-20 | T. Breeders, Inc. | Selective expansion of target cell populations |
US5702433A (en) | 1995-06-27 | 1997-12-30 | Arrow International Investment Corp. | Kink-resistant steerable catheter assembly for microwave ablation |
ATE365808T1 (de) | 1995-07-28 | 2007-07-15 | Marie Curie Cancer Care | Transportproteine und deren verwendungen |
FR2739621B1 (fr) | 1995-10-05 | 1997-12-05 | Centre Nat Rech Scient | Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives |
WO1997019172A1 (fr) | 1995-11-17 | 1997-05-29 | Asahi Kasei Kogyo Kabushiki Kaisha | Polypeptide suppresseur et de differenciation |
US5762069A (en) | 1995-12-29 | 1998-06-09 | Akos Biomedical, Inc. | Multiple sample biopsy forceps |
US5856155A (en) | 1996-02-23 | 1999-01-05 | The Johns Hopkins University School Of Medicine | Compounds and related methods for modulating potassium ion channels and assays for such compounds |
US5824031A (en) | 1996-02-28 | 1998-10-20 | Cardio Source | Apparatus and method for deflecting a tip of a lead or catheter |
US6132390A (en) | 1996-02-28 | 2000-10-17 | Eupalamus Llc | Handle for manipulation of a stylet used for deflecting a tip of a lead or catheter |
US5782748A (en) | 1996-07-10 | 1998-07-21 | Symbiosis Corporation | Endoscopic surgical instruments having detachable proximal and distal portions |
GB9615726D0 (en) | 1996-07-26 | 1996-09-04 | Medical Res Council | Anti-viral agent 11 |
US5955275A (en) | 1997-02-14 | 1999-09-21 | Arcaris, Inc. | Methods for identifying nucleic acid sequences encoding agents that affect cellular phenotypes |
US6017735A (en) | 1997-01-23 | 2000-01-25 | Marie Curie Cancer Care | Materials and methods for intracellular transport and their uses |
US6443949B2 (en) | 1997-03-13 | 2002-09-03 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
US6547787B1 (en) | 1997-03-13 | 2003-04-15 | Biocardia, Inc. | Drug delivery catheters that attach to tissue and methods for their use |
US6416510B1 (en) | 1997-03-13 | 2002-07-09 | Biocardia, Inc. | Drug delivery catheters that attach to tissue and methods for their use |
US6511477B2 (en) | 1997-03-13 | 2003-01-28 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
US6086582A (en) | 1997-03-13 | 2000-07-11 | Altman; Peter A. | Cardiac drug delivery system |
DE69841002D1 (de) | 1997-05-14 | 2009-09-03 | Univ British Columbia | Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln |
US6099832A (en) | 1997-05-28 | 2000-08-08 | Genzyme Corporation | Transplants for myocardial scars |
US5899914A (en) | 1997-06-11 | 1999-05-04 | Endius Incorporated | Surgical instrument |
US5851212A (en) | 1997-06-11 | 1998-12-22 | Endius Incorporated | Surgical instrument |
US6004295A (en) | 1997-06-26 | 1999-12-21 | An-Go-Gen Inc. | Catheters |
US7514074B2 (en) | 1997-07-14 | 2009-04-07 | Osiris Therapeutics, Inc. | Cardiac muscle regeneration using mesenchymal stem cells |
AU8401498A (en) | 1997-07-14 | 1999-02-10 | Osiris Therapeutics, Inc. | Cardiac muscle regeneration using mesenchymal stem cells |
GB9718609D0 (en) | 1997-09-02 | 1997-11-05 | Imp College Innovations Ltd | Fusion protein |
US6123699A (en) | 1997-09-05 | 2000-09-26 | Cordis Webster, Inc. | Omni-directional steerable catheter |
US7037648B1 (en) | 1997-11-07 | 2006-05-02 | John Hopkins University | Somatic transfer of modified genes to predict drug effects |
US5938603A (en) | 1997-12-01 | 1999-08-17 | Cordis Webster, Inc. | Steerable catheter with electromagnetic sensor |
US6203487B1 (en) | 1997-12-31 | 2001-03-20 | Thomas Jefferson University | Use of magnetic particles in the focal delivery of cells |
WO1999039624A1 (en) | 1998-02-05 | 1999-08-12 | Biosense Inc. | Intracardiac drug delivery |
JP2002507407A (ja) | 1998-03-23 | 2002-03-12 | ザイモジェネティクス,インコーポレイティド | 心臓由来幹細胞 |
US20010044619A1 (en) | 1998-04-08 | 2001-11-22 | Peter A. Altman | Cardiac drug delivery system and method for use |
US6296630B1 (en) | 1998-04-08 | 2001-10-02 | Biocardia, Inc. | Device and method to slow or stop the heart temporarily |
US6171610B1 (en) | 1998-04-24 | 2001-01-09 | University Of Massachusetts | Guided development and support of hydrogel-cell compositions |
US6165164A (en) | 1999-03-29 | 2000-12-26 | Cordis Corporation | Catheter for injecting therapeutic and diagnostic agents |
US6540725B1 (en) | 1998-06-04 | 2003-04-01 | Biosense Webster, Inc. | Injection catheter with controllably extendable injection needle |
DE19833476B4 (de) | 1998-07-24 | 2005-08-25 | Huss, Ralf, Dr. | Genetisch modifizierte CD34-Negative, adhärent wachsende hämatopoetische Stammzellen und deren Verwendung in der Gentherapie |
US6102887A (en) | 1998-08-11 | 2000-08-15 | Biocardia, Inc. | Catheter drug delivery system and method for use |
US6074408A (en) | 1998-10-13 | 2000-06-13 | Freeman; Kenneth V. | Modular medical instrument and method of using same |
US6153582A (en) | 1998-11-05 | 2000-11-28 | Bausch & Lomb Surgical, Inc. | Defined serumfree medical solution for ophthalmology |
US6572611B1 (en) | 1998-11-23 | 2003-06-03 | C. R. Bard, Inc. | Intracardiac grasp catheter |
US6193763B1 (en) | 1998-12-17 | 2001-02-27 | Robert A. Mackin | Apparatus and method for contemporaneous treatment and fluoroscopic mapping of body tissue |
AUPP785098A0 (en) | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
US6783510B1 (en) | 1999-07-08 | 2004-08-31 | C.R. Bard, Inc. | Steerable catheter |
US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
AU6519100A (en) | 1999-08-05 | 2001-03-05 | Biocardia, Inc. | A system and method for delivering thermally sensitive and reverse-thermal gelation matrials |
SE9903185D0 (sv) | 1999-09-08 | 1999-09-08 | Europ I Of Science Ab | Terapeutisk metod och anordning baserad på magnetism |
WO2001021767A2 (en) | 1999-09-24 | 2001-03-29 | Morphogen Pharmaceuticals, Inc. | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof |
US20030161817A1 (en) | 2001-03-28 | 2003-08-28 | Young Henry E. | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof |
US6716242B1 (en) | 1999-10-13 | 2004-04-06 | Peter A. Altman | Pulmonary vein stent and method for use |
CA2402502A1 (en) | 1999-10-13 | 2001-04-19 | Biocardia, Inc. | Pulmonary vein stent and method for use |
US6224587B1 (en) | 1999-11-22 | 2001-05-01 | C.R. Bard, Inc. | Steerable catheter |
AU4305101A (en) | 1999-11-22 | 2001-06-04 | Research Foundation Of The State University Of New York, The | Magnetic nanoparticles for selective therapy |
US6866843B2 (en) | 1999-12-06 | 2005-03-15 | Viacell, Inc. | Method of transplanting in a mammal and treating diabetes mellitus by administering a pseudo-islet like aggregate differentiated from a nestin-positive pancreatic stem cell |
AU784618B2 (en) | 1999-12-28 | 2006-05-18 | Kyowa Hakko Kogyo Co. Ltd. | Cells capable of differentiating into heart muscle cells |
CA2396348A1 (en) | 2000-01-14 | 2001-07-19 | Beth Israel Deaconess Medical Center | Cardiac-cell specific enhancer elements and uses thereof |
US6530944B2 (en) | 2000-02-08 | 2003-03-11 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
US6478776B1 (en) | 2000-04-05 | 2002-11-12 | Biocardia, Inc. | Implant delivery catheter system and methods for its use |
US6585716B2 (en) | 2000-04-05 | 2003-07-01 | Biocardia, Inc. | Method of treating the heart |
US20040087016A1 (en) | 2000-05-12 | 2004-05-06 | University Of Utah Research Foundation | Compositions and methods for cell dedifferentiation and tissue regeneration |
ES2309079T3 (es) | 2000-07-13 | 2008-12-16 | Abbott Cardiovascular Systems Inc. | Sistema de despliegue para material celular miocardico. |
CA2423592A1 (en) | 2000-07-31 | 2002-02-21 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
US7547674B2 (en) | 2001-06-06 | 2009-06-16 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
US20020098167A1 (en) | 2000-07-31 | 2002-07-25 | Piero Anversa | Methods and compositions for the repair and/or regeneration of damaged myocardium |
US20110091428A1 (en) | 2000-07-31 | 2011-04-21 | New York Medical College | Compositions of adult organ stem cells and uses thereof |
US7862810B2 (en) | 2000-07-31 | 2011-01-04 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
EP1324780A4 (en) | 2000-09-06 | 2005-06-22 | Univ Johns Hopkins | METHODS OF TREATING CARDIAC ARRHYTHMIA |
US6569105B1 (en) | 2000-09-14 | 2003-05-27 | Syntheon, Llc | Rotatable and deflectable biopsy forceps |
FR2814752A1 (fr) | 2000-10-02 | 2002-04-05 | Chru Lille | Procede d'obtention in vitro de cellules insulino- secretrices de mammifere et leurs utilisations |
US6511471B2 (en) | 2000-12-22 | 2003-01-28 | Biocardia, Inc. | Drug delivery catheters that attach to tissue and methods for their use |
CA2856986C (en) | 2001-02-14 | 2019-08-13 | Anthrogenesis Corporation | Post-partum mammalian placental stem cells for use in the treatment of neurological or renal diseases and disorders |
US20040168341A1 (en) | 2001-03-21 | 2004-09-02 | Petersen Peter Mosborg | Methods for performing operations, a housing for such methods, and furnishings for such housing |
AU2002306865A1 (en) | 2001-03-23 | 2003-03-03 | Warren J. Alilain | Generation of multipotent central nervous system stem cells |
IL158618A0 (en) | 2001-04-27 | 2004-05-12 | Univ Johns Hopkins | Biological pacemaker |
US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
US7026121B1 (en) | 2001-06-08 | 2006-04-11 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
CA2351156A1 (en) | 2001-07-04 | 2003-01-04 | Peter W. Zandstra | A bioprocess for the generation of pluripotent cell derived cells and tissues |
US6796963B2 (en) | 2001-07-10 | 2004-09-28 | Myocardial Therapeutics, Inc. | Flexible tissue injection catheters with controlled depth penetration |
CA2453438C (en) | 2001-07-12 | 2016-04-05 | Geron Corporation | Cells of the cardiomyocyte lineage produced from human pluripotent stem cells |
WO2003008535A2 (en) | 2001-07-20 | 2003-01-30 | Technion Research And Development Foundation Ltd. | Methods of generating human cardiac cells and tissues and uses thereof |
US7074175B2 (en) | 2001-07-25 | 2006-07-11 | Erik Schroeder Handy | Thermotherapy via targeted delivery of nanoscale magnetic particles |
US7731648B2 (en) | 2001-07-25 | 2010-06-08 | Aduro Biotech | Magnetic nanoscale particle compositions, and therapeutic methods related thereto |
US6997863B2 (en) | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
WO2003018780A1 (en) | 2001-08-27 | 2003-03-06 | Advanced Cell Technology, Inc. | De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
US7452532B2 (en) | 2001-09-30 | 2008-11-18 | Scicotec Gmbh | Transluminal application of adult stem cells for body organ tissue repair |
US6805860B1 (en) | 2001-09-30 | 2004-10-19 | Eckhard Alt | Method of transluminal application of myogenic cells for repair or replacement of heart tissue |
US20030082153A1 (en) | 2001-10-22 | 2003-05-01 | The Government Of The United States Of America | Stem cells that transform to beating cardiomyocytes |
KR100969344B1 (ko) | 2001-11-05 | 2010-07-09 | 메드제닉스 인코포레이티드 | 조직 기재 치료를 위한 폐쇄된 자동화 시스템, 이를 이용한 투약 및 투여 방법 |
DE10162353A1 (de) | 2001-12-18 | 2003-07-03 | Roehm Gmbh | Extrusionsdüse für Folien oder Platten mit seitlicher Schmelzeeinspeisung |
US20040014209A1 (en) | 2002-01-23 | 2004-01-22 | Lassar Andrew B. | Compositions and methods for modulating cell differentiation |
GB0202149D0 (en) | 2002-01-30 | 2002-03-20 | Univ Edinburgh | Pluripotency determining factors and uses thereof |
TWI288779B (en) | 2002-03-28 | 2007-10-21 | Blasticon Biotech Forschung | Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
US6866117B2 (en) | 2002-04-05 | 2005-03-15 | Wing Enterprises, Inc. | Light weight ladder systems and methods |
US7840261B2 (en) | 2002-06-05 | 2010-11-23 | Biocardia, Inc. | Catheter systems and methods for placing bi-ventricular pacing leads |
US20050176620A1 (en) | 2002-06-21 | 2005-08-11 | Prestwich Glenn D. | Crosslinked compounds and methods of making and using thereof |
US20040018174A1 (en) | 2002-07-23 | 2004-01-29 | Boston Scientific Corporation | Cell therapy for regeneration |
US20040110287A1 (en) | 2002-07-29 | 2004-06-10 | Es Cell International Pte Ltd. | Multi-step method for the differentiation of insulin positive, glucose responsive cells |
WO2004019767A2 (en) | 2002-08-29 | 2004-03-11 | Baylor College Of Medicine | Heart derived cells for cardiac repair |
AU2003290601A1 (en) | 2002-11-05 | 2004-06-03 | The Brigham And Women's Hospital, Inc. | Mesenchymal stem cells and methods of use thereof |
US7794702B2 (en) | 2003-01-15 | 2010-09-14 | The Trustees Of Columbia University In The City Of New York | Mesenchymal stem cells as a vehicle for ion channel transfer in syncytial structures |
WO2004070013A2 (en) | 2003-01-31 | 2004-08-19 | The Regents Of The University Of California | Use of islet 1 as a marker for isolating or generating stem cells |
DE10331439B3 (de) | 2003-07-10 | 2005-02-03 | Micromod Partikeltechnologie Gmbh | Magnetische Nanopartikel mit verbesserten Magneteigenschaften |
JP2004248382A (ja) | 2003-02-12 | 2004-09-02 | Mitsubishi Motors Corp | ハイブリッド車 |
JP2006520202A (ja) | 2003-03-04 | 2006-09-07 | インターツェル・アクチェンゲゼルシャフト | ストレプトコッカス・ピオゲネス抗原 |
US7837631B2 (en) | 2003-03-14 | 2010-11-23 | Boston Scientific Scimed Inc. | Biopsy forceps with removable jaw segments |
US20060041182A1 (en) | 2003-04-16 | 2006-02-23 | Forbes Zachary G | Magnetically-controllable delivery system for therapeutic agents |
US20040214182A1 (en) | 2003-04-25 | 2004-10-28 | Vinod Sharma | Genetic modification of targeted regions of the cardiac conduction system |
US7329638B2 (en) | 2003-04-30 | 2008-02-12 | The Regents Of The University Of Michigan | Drug delivery compositions |
US20060025713A1 (en) | 2003-05-12 | 2006-02-02 | Alex Rosengart | Magnetic particle-based therapy |
CA2431425A1 (en) | 2003-06-05 | 2004-12-05 | Angiogene, Inc. | Epas1 gene transfer to improve cell therapy |
GB0313259D0 (en) | 2003-06-09 | 2003-07-16 | Consejo Superior Investigacion | Magnetic nanoparticles |
ES2265199B1 (es) | 2003-06-12 | 2008-02-01 | Cellerix, S.L. | Celulas madre adultas multipotentes procedentes de condrocitos desdiferenciados y sus aplicaciones. |
US20070053839A1 (en) | 2003-06-12 | 2007-03-08 | Jianyi Zhang | Directing cells to target tissues organs |
WO2005001079A2 (en) | 2003-06-27 | 2005-01-06 | Ethicon, Incorporated | Soft tissue repair and regeneration using postpartum-derived cells |
JP3889026B2 (ja) | 2003-06-30 | 2007-03-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 磁性細胞およびその使用方法 |
US20060205071A1 (en) | 2003-07-17 | 2006-09-14 | Gamida-Cell Ltd. | Methods for ex-vivo expanding stem/progenitor cells |
ITRM20030376A1 (it) | 2003-07-31 | 2005-02-01 | Univ Roma | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. |
US20080213812A1 (en) | 2003-09-29 | 2008-09-04 | Andrews William H | Methods and compositions for modulating telomerase reverse transcriptase (TERT) expression |
JP2005110565A (ja) | 2003-10-07 | 2005-04-28 | Nobuya Yamanaka | 分化多能性維持剤 |
US7280863B2 (en) | 2003-10-20 | 2007-10-09 | Magnetecs, Inc. | System and method for radar-assisted catheter guidance and control |
CN1537646A (zh) | 2003-10-22 | 2004-10-20 | 高春平 | 肿瘤局部综合治疗方法和装置 |
US20050090732A1 (en) | 2003-10-28 | 2005-04-28 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles |
ES2398239T3 (es) | 2003-11-10 | 2013-03-14 | The Scripps Research Institute | Composiciones y procedimientos para inducir la desdiferenciación celular |
GB0329310D0 (en) | 2003-12-18 | 2004-01-21 | Univ Keele | Method |
US7625581B2 (en) | 2003-12-19 | 2009-12-01 | Ethicon, Inc. | Tissue scaffolds for use in muscoloskeletal repairs |
US20070196281A1 (en) | 2003-12-31 | 2007-08-23 | Sungho Jin | Method and articles for remote magnetically induced treatment of cancer and other diseases, and method for operating such article |
WO2005076743A2 (en) | 2004-02-17 | 2005-08-25 | Yeda Research And Development Co. Ltd. | Disaccharide molecules and derivatives thereof and methods of using same |
US20050260748A1 (en) | 2004-02-27 | 2005-11-24 | Michigan State University | Adult stem cells and uses thereof |
US20050214938A1 (en) | 2004-03-26 | 2005-09-29 | Gold Joseph D | Cardiac bodies: clusters of spontaneously contracting cells for regenerating cardiac function |
US20090074669A1 (en) | 2004-03-31 | 2009-03-19 | Ebert Steven N | PNMT as a novel marker for progenitor cells |
US20070231393A1 (en) | 2004-05-19 | 2007-10-04 | University Of South Carolina | System and Device for Magnetic Drug Targeting with Magnetic Drug Carrier Particles |
US7259011B2 (en) | 2004-05-20 | 2007-08-21 | Paul Lucas | Pluripotent adult stem cells |
JP2006006125A (ja) | 2004-06-22 | 2006-01-12 | Nipro Corp | 骨髄単核細胞の調製方法及び細胞調製装置 |
WO2006004910A2 (en) | 2004-06-28 | 2006-01-12 | Transtarget Inc. | Improved bispecific antibodies |
JP2008505104A (ja) | 2004-07-01 | 2008-02-21 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | 免疫抑制性エキソソーム |
WO2006014156A1 (en) | 2004-07-02 | 2006-02-09 | Macropore Biosurgery, Inc. | Systems and methods for isolating and using clinically safe adipose derived regenerative cells |
US20070196918A1 (en) | 2004-07-15 | 2007-08-23 | Sayre Chauncey B | Reprogramming of adult human testicular stem cells to pluripotent germ-line stem cells |
CA2575446C (en) | 2004-08-03 | 2014-03-25 | Becton, Dickinson And Company | Use of magnetic material to direct isolation of compounds and fractionation of multipart samples |
ES2313805B1 (es) | 2004-10-04 | 2009-12-23 | Cellerix, S.L. | Identificacion y aislamiento de celulas multipotentes de tejido mesenquimal no osteocondral. |
US8431397B2 (en) | 2004-09-14 | 2013-04-30 | The Trustees Of Columbia University In The City Of New York | Differentiation of human mesenchymal stem cells to cardiac progenitor cells that promote cardiac repair |
US20060234375A1 (en) | 2004-09-30 | 2006-10-19 | Doronin Sergey V | Use of human stem cells and/or factors they produce to promote adult mammalian cardiac repair through cardiomyocyte cell division |
WO2006044204A2 (en) | 2004-10-05 | 2006-04-27 | University Of Georgia Research Foundation, Inc. | Neuronal progenitors from feeder-free human embryonic stem cell culture |
FR2877571B1 (fr) | 2004-11-05 | 2007-04-13 | Nanobiotix Sarl | Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations |
EP1809740B1 (en) | 2004-11-08 | 2018-08-29 | The Johns Hopkins University | Cardiac stem cells |
US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
US7402151B2 (en) | 2004-12-17 | 2008-07-22 | Biocardia, Inc. | Steerable guide catheters and methods for their use |
EP1674128A1 (en) | 2004-12-22 | 2006-06-28 | Steinbeis-Transferzentrum für Herz-Kreislaufforschung | Magnetic pole matrices useful for tissue engineering and treatment of disease |
US7850960B2 (en) | 2004-12-30 | 2010-12-14 | University Of Washington | Methods for regulation of stem cells |
WO2006081190A2 (en) | 2005-01-25 | 2006-08-03 | Five Prime Therapeutics, Inc. | Compositions and methods for treating cardiac conditions |
EP1857544B1 (en) | 2005-03-04 | 2012-06-20 | Kyoto University | Pluripotent stem cell derived from cardiac tissue |
KR101617319B1 (ko) | 2005-04-12 | 2016-05-02 | 메소블라스트, 아이엔씨. | 조직 비특이적인 알카리 포스파타제에 의한 다분화성 성체 세포의 분리 |
DE102005016873A1 (de) | 2005-04-12 | 2006-10-19 | Magforce Nanotechnologies Ag | Nanopartikel-Wirstoff-Konjugate |
US7846393B2 (en) | 2005-04-21 | 2010-12-07 | California Institute Of Technology | Membrane filter for capturing circulating tumor cells |
GB0508110D0 (en) | 2005-04-22 | 2005-06-01 | Univ Keele | Gene delivery |
WO2006118914A2 (en) | 2005-04-29 | 2006-11-09 | Children's Medical Center Corporation | Methods of increasing proliferation of adult mammalian cardiomyocytes through p38 map kinase inhibition |
US20070003528A1 (en) | 2005-06-29 | 2007-01-04 | Paul Consigny | Intracoronary device and method of use thereof |
US20070014869A1 (en) | 2005-07-15 | 2007-01-18 | Cormatrix Cardiovascular, Inc. | Compositions for reconstruction, replacement or repair of intracardiac tissue |
ES2836764T3 (es) | 2005-08-03 | 2021-06-28 | Astellas Inst For Regenerative Medicine | Métodos mejorados de reprogramación de células somáticas animales |
US20070048383A1 (en) | 2005-08-25 | 2007-03-01 | Helmus Michael N | Self-assembled endovascular structures |
US20070054397A1 (en) | 2005-08-26 | 2007-03-08 | Harald Ott | Adult cardiac uncommitted progenitor cells |
EP1931783A1 (en) | 2005-09-09 | 2008-06-18 | The Trustees of Columbia University in the City of New York | Chimeric hcn channels |
WO2007047465A1 (en) | 2005-10-13 | 2007-04-26 | Anthrogenesis Corporation | Production of oligodendrocytes from placenta-derived stem cells |
US7736346B2 (en) | 2005-10-18 | 2010-06-15 | Biocardia, Inc. | Bio-interventional therapeutic treatments for cardiovascular diseases |
JP5191235B2 (ja) | 2005-10-21 | 2013-05-08 | 中外製薬株式会社 | 心疾患治療剤 |
CN100509059C (zh) | 2005-10-25 | 2009-07-08 | 南京工业大学 | 磁热疗用纳米磁粉-抗cea抗体靶向药物 |
CN100355454C (zh) | 2005-10-25 | 2007-12-19 | 南京工业大学 | 磁热疗用纳米磁粉-抗人肝癌单抗HAb18靶向药物 |
WO2007048202A1 (en) | 2005-10-25 | 2007-05-03 | Women's & Children's Health Research Institute | Methods and compositions for modulating wound repair |
EP4223769A3 (en) | 2005-12-13 | 2023-11-01 | Kyoto University | Nuclear reprogramming factor |
WO2007133812A2 (en) | 2005-12-30 | 2007-11-22 | Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine | Improved carriers for delivery of nucleic acid agents to cells and tissues |
US7875451B2 (en) | 2006-01-19 | 2011-01-25 | The University Of Washington | Formulation to improve survival of transplanted cells |
US8119123B2 (en) | 2006-02-16 | 2012-02-21 | New York Medical College | Compositions comprising vascular and myocyte progenitor cells and methods of their use |
US7869854B2 (en) | 2006-02-23 | 2011-01-11 | Magnetecs, Inc. | Apparatus for magnetically deployable catheter with MOSFET sensor and method for mapping and ablation |
WO2007113572A1 (en) | 2006-04-03 | 2007-10-11 | Keele University | Targeted therapy |
WO2007146319A2 (en) | 2006-06-13 | 2007-12-21 | Symphony Medical, Inc. | Methods and apparatus for using polymer-based beads and hydrogels for cardiac applications |
US8568286B2 (en) | 2006-06-14 | 2013-10-29 | Cardiac Pacemakers, Inc. | Methods to position therapeutic agents using a magnetic field |
WO2008066965A2 (en) | 2006-06-23 | 2008-06-05 | The Regents Of The University Of California | Articles comprising large-surface-area bio-compatible materials and methods for making and using them |
US20080031854A1 (en) | 2006-07-11 | 2008-02-07 | Prestwich Glenn D | Thiolated macromolecules and methods of making and using thereof |
CN101553889A (zh) | 2006-09-05 | 2009-10-07 | 哥伦布纳米制品公司 | 磁性颗粒及其制备方法和使用方法 |
AU2007299748A1 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | miR-15, miR-26, miR -31,miR -145, miR-147, miR-188, miR-215, miR-216 miR-331, mmu-miR-292-3p regulated genes and pathways as targets for therapeutic intervention |
WO2008040027A2 (en) | 2006-09-28 | 2008-04-03 | The Regents Of The University Of California | Directed differentiation and maturation of stem cell-derived cardiomyocytes |
EP2476762B1 (de) | 2006-10-09 | 2014-01-08 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) zur Diagnose und Therapie von Herzerkrankungen |
PL2084268T3 (pl) | 2006-10-23 | 2019-08-30 | Celularity, Inc. | Sposoby i kompozycje do leczenia ubytków kości z użyciem populacji komórek łożyska |
US7787949B2 (en) | 2006-10-30 | 2010-08-31 | Medtronic, Inc. | Biological pacemaker compositions and systems incorporating interstitial cells of Cajal |
CA2668826A1 (en) | 2006-11-07 | 2008-05-15 | Keck Graduate Institute | Enriched stem cell and progenitor cell populations, and methods of producing and using such populations |
KR101240487B1 (ko) | 2006-11-09 | 2013-03-08 | 더 존스 홉킨스 유니버시티 | 성체 포유동물 심근세포의 심장 줄기 세포로의 역분화 |
US8076305B2 (en) | 2006-11-30 | 2011-12-13 | Medtronic, Inc. | Biological pacemakers including mutated hyperpolarization-activated cyclic nucleotide-gated (HCN) channels |
KR100830889B1 (ko) | 2006-12-18 | 2008-05-21 | 주식회사 케이티 | 세툭시맵이 결합된 나노 입자 및 이의 제조 방법 |
DE102007008650B4 (de) | 2007-02-20 | 2012-06-06 | Charité - Universitätsmedizin Berlin | Zellen zur Therapie des Herzens |
CN101743306A (zh) | 2007-03-23 | 2010-06-16 | 威斯康星校友研究基金会 | 体细胞重编程 |
MX348010B (es) | 2007-04-07 | 2017-05-23 | Whitehead Inst Biomedical Res | Reprogramacion de celulas somaticas. |
US8496926B2 (en) | 2007-04-16 | 2013-07-30 | Biocardia, Inc. | Treatment for chronic myocardial infarction |
US9205112B2 (en) | 2007-04-23 | 2015-12-08 | Creative Medical Health, Inc. | Combination treatment of cardiovascular disease |
US20080297287A1 (en) | 2007-05-30 | 2008-12-04 | Magnetecs, Inc. | Magnetic linear actuator for deployable catheter tools |
FI20075417A0 (fi) | 2007-06-05 | 2007-06-05 | Marjo-Riitta Suuronen | Koostumuksia ja menetelmiä alkion kantasolujen kasvatukseen |
WO2009032456A2 (en) | 2007-08-01 | 2009-03-12 | Primegen Biotech Llc | Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state |
US20090136582A1 (en) | 2007-08-03 | 2009-05-28 | Albrecht Ralph M | Colloidal magnetic nanobioparticles for cytotoxicity and drug delivery |
WO2009023510A1 (en) | 2007-08-09 | 2009-02-19 | Boston Scientific Scimed, Inc. | Catheter devices for myocardial injections or other uses |
US20090081276A1 (en) | 2007-08-13 | 2009-03-26 | Eben Alsberg | Bioresorbable implant composition |
US20090081170A1 (en) | 2007-09-13 | 2009-03-26 | Paul Riley | Cardiac progenitor cells |
WO2009040789A2 (en) | 2007-09-24 | 2009-04-02 | Technion Research & Development Foundation Ltd. | T cell subpopulations capable of treating cancer |
JP5496675B2 (ja) | 2007-10-10 | 2014-05-21 | 国立大学法人京都大学 | 細胞移植療法に用いられる心疾患治療薬 |
EP2209481B1 (en) | 2007-10-15 | 2013-03-13 | Fresenius Medical Care Deutschland GmbH | Use of microvesicles (mvs) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularly in the treatment of diabetes by pancreatic islet transplantation, and related method |
WO2009058818A2 (en) | 2007-10-29 | 2009-05-07 | The Board Of Regents Of The University Of Texas System | Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling |
DE102007052114B4 (de) | 2007-10-30 | 2011-01-05 | T2Cure Gmbh | Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle |
US8617877B2 (en) | 2007-11-02 | 2013-12-31 | The Johns Hopkins University | Cardiac stem cell and myocyte secreted paracrine factors |
KR20100099158A (ko) | 2007-11-09 | 2010-09-10 | 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 | 심근세포 생존과 심장 회복을 제어하는 MIR-15 집단의 마이크로RNAs |
AU2008323719B2 (en) | 2007-11-09 | 2013-04-04 | New York Medical College | Methods for the repair and/or regeneration of damaged myocardium using variants of hepatocyte growth factor |
US8968699B2 (en) | 2007-11-15 | 2015-03-03 | The Regents Of The University Of California | Switchable nano-vehicle delivery systems, and methods for making and using them |
WO2009067644A1 (en) | 2007-11-21 | 2009-05-28 | University Of Miami | Compositions, systems and methods for obtaining and expanding insulin-producing cells |
US9186317B2 (en) | 2007-11-26 | 2015-11-17 | Stc.Unm | Active nanoparticles and method of using |
EP2245140A2 (en) | 2007-11-30 | 2010-11-03 | New York Medical College | Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure |
US8512696B2 (en) | 2007-11-30 | 2013-08-20 | Autologous, Llc | Methods of isolating non-senescent cardiac stem cells and uses thereof |
US8124071B2 (en) | 2007-11-30 | 2012-02-28 | New York Medical College | Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells |
WO2009073518A1 (en) | 2007-11-30 | 2009-06-11 | New York Medical College | Methods of isolating non-senescent cardiac stem cells and uses thereof |
US9090894B2 (en) | 2007-12-17 | 2015-07-28 | California Institute Of Technology | Modulating immune system development and function through microRNA MIR-146 |
US20110110897A1 (en) | 2008-01-11 | 2011-05-12 | Schwarz Richard P | Adult Human Cardiac-Derived Progenitor Cells |
US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
US7999025B2 (en) | 2008-01-28 | 2011-08-16 | University Of Utah Research Foundation | Asymmetrically-functionalized nanoparticles organized on one-dimensional chains |
WO2009100137A2 (en) | 2008-02-04 | 2009-08-13 | University Of Miami | Magnetic cells for localizing delivery and tissue repair |
KR101640381B1 (ko) * | 2008-02-22 | 2016-07-18 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 중간엽 줄기세포 입자 |
WO2009103818A1 (en) | 2008-02-22 | 2009-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for obtaining progenitor cells and uses thereof in the treatment of tissue or organ damage |
WO2009120702A2 (en) | 2008-03-25 | 2009-10-01 | Emory University | Elemental iron nanoparticles |
WO2009136283A2 (en) | 2008-05-08 | 2009-11-12 | Coretherapix Slu | Multipotent adult stem cell population |
WO2009147519A1 (en) * | 2008-06-06 | 2009-12-10 | Centre National De La Recherche Scientifique - Cnrs- | Use of endo-lysosomal system and secreted vesicles (exosome-like) in treatments and diagnostics based on small rna and experimental study of small rna |
US8193161B2 (en) | 2008-06-09 | 2012-06-05 | New York Medical College | Compositions comprising cardiac stem cells overexpressing specific micrornas and methods of their use in repairing damaged myocardium |
CN102056591B (zh) | 2008-06-11 | 2013-12-11 | 刘彦仿 | 脂质体药剂及其制备方法和用途 |
US8481492B2 (en) | 2008-06-13 | 2013-07-09 | Life & Brain Gmbh | Fusion protein and use thereof |
EP2300607A2 (en) | 2008-06-26 | 2011-03-30 | Spectrum Health Innovations, LLC | Method for treating and preventing radiation damage using genetically modified mesenchymal stem cells |
US20130309304A1 (en) | 2008-08-05 | 2013-11-21 | Bernardo Nadal-Ginard | Compounds and methods |
GB0814302D0 (en) | 2008-08-05 | 2008-10-01 | Coretherapix Slu | Compounds and methods |
US20110092961A1 (en) | 2008-08-13 | 2011-04-21 | Searete Llc | Artificial cells |
US8172831B2 (en) | 2008-09-02 | 2012-05-08 | Abbott Cardiovascular Systems Inc. | Catheter configured for incremental rotation |
WO2010059806A2 (en) | 2008-11-20 | 2010-05-27 | Cedars-Sinai Medical Center | Generation of induced pluripotent stem cells without the use of viral vectors |
WO2010075286A1 (en) | 2008-12-24 | 2010-07-01 | University Of Washington | MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY |
WO2010083466A1 (en) | 2009-01-16 | 2010-07-22 | Cedars-Sinai Medical Center | Methods and compositions for cardiac tissue regeneration |
EP2228444A1 (en) | 2009-03-09 | 2010-09-15 | Julius-Maximilians-Universität Würzburg | microRNA for diagnostic and therapeutic purposes in cardiovascular diseases |
WO2010118059A1 (en) | 2009-04-06 | 2010-10-14 | Capricor, Inc. | Systems and methods for cardiac tissue repair |
BRPI1016193A2 (pt) | 2009-04-29 | 2017-03-21 | Nutrition Physiology Company Llc | inibição do desenvolvimento de patógeno sobre materiais de planta usando microrganismos que produzem ácido láctico. |
WO2010135570A1 (en) | 2009-05-20 | 2010-11-25 | Board Of Regents, The University Of Texas System | Identification of micro-rnas involved in post-myocardial infarction remodeling and heart failure |
JP5667180B2 (ja) | 2009-07-01 | 2015-02-12 | イオン メディックス インコーポレイテッド | 哺乳類の有核細胞に由来するマイクロベシクル及びその用途 |
US20120258093A1 (en) | 2009-08-20 | 2012-10-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
US8609617B2 (en) | 2009-09-04 | 2013-12-17 | University Of Miami | KLF family members regulate intrinsic axon regeneration ability |
WO2011029903A1 (en) | 2009-09-10 | 2011-03-17 | Flemming Velin | Method for the preparation of micro-rna and its therapeutic application |
WO2011056685A1 (en) | 2009-10-27 | 2011-05-12 | Cedars-Sinai Medical Center | External magnetic force for targeted cell delivery with enhanced cell retention |
US20150010640A1 (en) | 2009-10-27 | 2015-01-08 | Cedars-Sinai Medical Center | Bi-functional compositions for targeting cells to diseased tissues and methods of using same |
US9095629B2 (en) | 2009-10-30 | 2015-08-04 | Northwestern University | Magnetic nanostructures as theranostic agents |
EP2498796B1 (en) | 2009-11-09 | 2017-12-27 | AAL Scientifics, Inc. | Treatment of heart disease |
EP2498797A4 (en) | 2009-11-09 | 2013-12-25 | Brigham & Womens Hospital | TREATMENT OF CARDIOPATHY |
WO2011062244A1 (ja) | 2009-11-18 | 2011-05-26 | Kuroda Masahiko | キャリア、その製造方法およびその用途 |
EP2327781A1 (en) | 2009-11-27 | 2011-06-01 | RWTH Aachen | Micro-RNA and tissue repair |
US20110135577A1 (en) | 2009-12-03 | 2011-06-09 | National Taiwan University | Superparamagnetic nanoparticles IN MEDICAL THERAPEUTICS and manufacturing method THEREOF |
JP2013514372A (ja) | 2009-12-15 | 2013-04-25 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 虚血および虚血−再灌流傷害におけるマイクロrna調節 |
WO2011082038A2 (en) | 2009-12-31 | 2011-07-07 | Fate Therapeutics, Inc. | Improved reprogramming compositions |
EP2371370A1 (en) | 2010-04-01 | 2011-10-05 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Antagonists of miRNA-29 expression and their use in the prevention and treatment of aortic aneurysms and atherosclerotic plaque destabilization |
WO2011127625A1 (zh) | 2010-04-13 | 2011-10-20 | 江苏命码生物科技有限公司 | 一种调节生物体内微小核糖核酸含量的方法及其用途 |
US9517250B2 (en) | 2010-04-28 | 2016-12-13 | The J. David Gladstone Institutes | Methods for generating cardiomyocytes |
US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
EP2385120A1 (en) | 2010-05-04 | 2011-11-09 | Justus-Liebig- Universitat Giessen | Use of anti-miRNA antisense oligonucleotides for the treatment of pulmonary hypertension |
JP5974215B2 (ja) | 2010-05-12 | 2016-08-24 | リージェンメド(ケイマン)エルティーディー. | 生理活性腎臓細胞 |
ES2718303T3 (es) | 2010-06-10 | 2019-07-01 | Midatech Ltd | Nanopartículas que portan péptidos |
US8980279B2 (en) | 2010-07-26 | 2015-03-17 | Qu Biologics | Personalized site-specific immunomodulation |
CN103153376B (zh) | 2010-08-06 | 2018-04-20 | 通用医院公司以麻省总医院名义经营 | 用于细胞处理相关应用的系统和设备 |
AU2011288262A1 (en) | 2010-08-13 | 2013-04-04 | The University Court Of The University Of Glasgow | Therapeutic uses of microvesicles and related microRNAs |
US20120093885A1 (en) | 2010-10-18 | 2012-04-19 | Northwestern University | Therapeutic vesicles |
EP2446929A1 (en) | 2010-10-27 | 2012-05-02 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Microvesicles derived from atheroprotective endothelial cells for the treatment and prevention of atherosclerotic diseases |
WO2012065027A2 (en) | 2010-11-11 | 2012-05-18 | University Of Miami | Compositions, kits and methods for treatment of cardiovascular, immunological, and inflammatory diseases |
SG183579A1 (en) | 2011-02-11 | 2012-09-27 | Agency Science Tech & Res | Methods of detecting therapeutic exosomes |
EP2683389B1 (en) | 2011-03-11 | 2017-05-03 | Children's Medical Center Corporation | Methods and compositions relating to mesenchymal stem cell exosomes |
US8871731B2 (en) | 2011-03-16 | 2014-10-28 | Migagen Therapeutics, Inc. | Micro-RNA for the regulation of cardiac apoptosis and contractile function |
AU2012236707B2 (en) | 2011-03-29 | 2017-07-20 | Asterias Biotherapeutics, Inc. | Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells |
WO2012149557A1 (en) | 2011-04-28 | 2012-11-01 | New York University | miR-33 INHIBITORS AND USES THEREOF TO DECREASE INFLAMMATION |
WO2012162741A1 (en) | 2011-06-01 | 2012-12-06 | Monash University | Enrichment of cardiomyocytes |
EP2535412A1 (en) | 2011-06-17 | 2012-12-19 | Universitat Pompeu-Fabra | New treatment for muscular dystrophies |
EP2549399A1 (en) | 2011-07-19 | 2013-01-23 | Koninklijke Philips Electronics N.V. | Assessment of Wnt pathway activity using probabilistic modeling of target gene expression |
US8802144B2 (en) | 2011-08-25 | 2014-08-12 | Wisconsin Alumni Research Foundation | 3-dimensional cardiac fibroblast derived extracellular matrix |
WO2013048734A1 (en) | 2011-09-28 | 2013-04-04 | Tufts Medical Center, Inc. | Treatment and prevention of cardiovascular disease with cell derived lipid vesicles, microvesicles and exosomes |
US20130280205A1 (en) | 2012-01-13 | 2013-10-24 | Georgia Regents University | Activators of SGK-1 for Use as Cardioprotective Agents |
KR101389850B1 (ko) | 2012-05-04 | 2014-04-29 | 이화여자대학교 산학협력단 | 심장전구세포의 배양방법 및 그 용도 |
WO2013170170A2 (en) | 2012-05-10 | 2013-11-14 | Board Of Regents Of The University Of Nebraska | Compositions and methods for gene therapy |
EP2861238A4 (en) | 2012-06-05 | 2016-03-16 | Capricor Inc | OPTIMIZED METHODS FOR GENERATING CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY |
EP2687219A1 (en) | 2012-07-18 | 2014-01-22 | Universität Duisburg-Essen | Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions |
EP2877187B1 (en) | 2012-07-19 | 2019-06-12 | Reneuron Limited | Stem cell microparticles |
EP2882445B1 (en) * | 2012-08-13 | 2019-04-24 | Cedars-Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
US9492484B2 (en) | 2012-09-27 | 2016-11-15 | The Regents Of The University Of California | Cardiosphere derived cell population and methods of use |
EP2914273B1 (en) | 2012-10-26 | 2018-07-04 | Cedars-Sinai Medical Center | Therapeutic cells depleted of specific subpopulations of cells for use in tissue repair of regeneration |
CA2899090A1 (en) | 2013-01-24 | 2014-07-31 | Bernardo Nadal-Ginard | Modulation of cardiac stem-progenitor cell differentiation, assays and uses thereof |
US10583103B2 (en) | 2013-03-13 | 2020-03-10 | University Of Cincinnati | Method of treating heart failure with preserved ejection fraction with probenecid |
US20140275976A1 (en) | 2013-03-15 | 2014-09-18 | Adventist Health System/Sunbelt, Inc. | Global Ventricular Cardiac Diastolic Function Evaluation System and Associated Methods |
US10208351B2 (en) | 2013-10-18 | 2019-02-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | RNY-derived small RNAs as biomarkers for atherosclerosis-related disorders |
US11377639B2 (en) | 2013-11-15 | 2022-07-05 | Wisconsin Alumni Research Foundation | Lineage reprogramming to induced cardiac progenitor cells (iCPC) by defined factors |
SI3076949T1 (sl) | 2013-12-04 | 2020-01-31 | Board Of Regents, The University Of Texas System | Postopek za izoliranje eksosomov, ki izvirajo iz rakavih celic |
PT3083997T (pt) | 2013-12-20 | 2020-11-03 | Univ Lausanne | Utilizações diagnósticas, prognósticas e terapêuticas de rnas longos não codificadores para doenças cardíacas e medicina regenerativa |
EP3102191A1 (en) | 2014-02-05 | 2016-12-14 | Stc.Unm | Exosomes as a therapeutic for cancer |
US20150328263A1 (en) | 2014-05-14 | 2015-11-19 | University Of Maryland, Baltimore | Cardiac stem cells for cardiac repair |
AU2015327812B2 (en) | 2014-10-03 | 2021-04-15 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
EP3204117A4 (en) | 2014-10-06 | 2018-05-09 | Cedars-Sinai Medical Center | Polarization of macrophages to a healing phenotype by cardiosphere-derived cells and by the exosomes secreted by such cells |
JP2017537630A (ja) | 2014-12-03 | 2017-12-21 | カプリコール,インコーポレイテッド | 低酸素培養条件におけるエクソソームの生成方法 |
US10131878B2 (en) | 2015-04-06 | 2018-11-20 | Wisconsin Alumni Research Foundation | Methods for epicardial differentiation of human pluripotent stem cells |
KR101818560B1 (ko) | 2015-05-18 | 2018-01-16 | 가톨릭관동대학교기술지주 주식회사 | 줄기세포 유래 미세소포체를 포함하는 부정맥 예방 또는 치료용 약제학적 조성물 |
US10624849B2 (en) | 2015-09-28 | 2020-04-21 | Northwestern University | Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites |
WO2017123662A1 (en) | 2016-01-11 | 2017-07-20 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
WO2017147594A1 (en) | 2016-02-26 | 2017-08-31 | Yale University | COMPOSITIONS AND METHODS OF USING piRNAS IN CANCER DIAGNOSTICS AND THERAPEUTICS |
WO2017160884A1 (en) | 2016-03-14 | 2017-09-21 | Capricor, Inc. | Methods of treating ocular inflammation and chemical injuries of the eye with extracellular vesicles |
US11458097B2 (en) | 2016-03-30 | 2022-10-04 | The University Of North Carolina At Chapel Hill | Biological agent-exosome compositions and uses thereof |
US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
WO2018057542A1 (en) | 2016-09-20 | 2018-03-29 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
AU2018255346B2 (en) | 2017-04-19 | 2024-05-02 | Capricor Inc | Methods and compositions for treating skeletal muscular dystrophy |
PL3431609T3 (pl) | 2017-07-17 | 2020-11-02 | Masarykova Univerzita | Sposób diagnozowania raka jelita grubego |
JP2020529477A (ja) | 2017-08-04 | 2020-10-08 | シーダーズ—シナイ メディカル センター | がんの治療及び防止のためのカルディオスフィア由来細胞及びその細胞外小胞 |
US11667916B2 (en) | 2017-09-08 | 2023-06-06 | Korea University Research And Business Foundation | Composition for preventing or treating liver fibrosis, containing exosome or exosome-derived ribonucleic acid |
WO2019126068A1 (en) | 2017-12-20 | 2019-06-27 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
EP3746137A4 (en) | 2018-01-30 | 2021-11-24 | Capricor, Inc. | ACTIVATION-INDUCED TISSUE EFFECTIVE CELLS SUITABLE FOR CELL THERAPY AND EXTRACELLULAR VESICLES DERIVED THEREOF |
WO2019152549A1 (en) | 2018-02-05 | 2019-08-08 | Cedars-Sinai Medical Center | Methods for therapeutic use of exosomes and y-rnas |
CA3139514A1 (en) | 2019-05-08 | 2020-11-12 | Cedars-Sinai Medical Center | Therapeutically active cells and exosomes |
WO2021178514A1 (en) | 2020-03-04 | 2021-09-10 | Cedars-Sinai Medical Center | Cardiosphere-derived cells, exosomes derived therefrom, and methods of using same to treat volumetric muscle loss |
US20230141499A1 (en) | 2020-03-20 | 2023-05-11 | Cedars-Sinai Medical Center | Cardiosphere-derived cell (cdc) therapy for the treatment of viral infections |
-
2013
- 2013-08-13 EP EP13829234.7A patent/EP2882445B1/en active Active
- 2013-08-13 CA CA2881394A patent/CA2881394A1/en active Pending
- 2013-08-13 US US14/421,355 patent/US9828603B2/en active Active
- 2013-08-13 WO PCT/US2013/054732 patent/WO2014028493A2/en active Application Filing
- 2013-08-13 JP JP2015527540A patent/JP6433896B2/ja active Active
- 2013-08-13 EP EP19163788.3A patent/EP3563859B1/en active Active
- 2013-08-13 AU AU2013302799A patent/AU2013302799B2/en active Active
-
2017
- 2017-10-23 US US15/790,962 patent/US10457942B2/en active Active
-
2018
- 2018-11-07 JP JP2018209427A patent/JP6726726B2/ja active Active
-
2019
- 2019-09-16 US US16/572,101 patent/US11220687B2/en active Active
-
2021
- 2021-11-29 US US17/537,005 patent/US20220119813A1/en active Pending
Non-Patent Citations (4)
Title |
---|
HU S, ET AL.: "MicroRNA-210 as a novel therapy for treatment of ischemic heart disease", CIRCULATION, vol. Vol.122, suppl.1, JPN6017024505, 14 September 2010 (2010-09-14), pages 124 - 131, ISSN: 0003827851 * |
LAI RC, ET AL.: "Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury", STEM CELL RESEARCH, vol. 4, no. 3, JPN6017024498, 2010, pages 214 - 222, XP055555858, ISSN: 0003827852, DOI: 10.1016/j.scr.2009.12.003 * |
LI TS, ET AL.: "Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 59, no. 10, JPN6017024501, 6 March 2012 (2012-03-06), pages 942 - 953, XP028462740, ISSN: 0003827854, DOI: 10.1016/j.jacc.2011.11.029 * |
VRIJSEN KR, ET AL.: "Cardiomyocyte progenitor cell-derived exosomes stimulate migration of endothelial cells", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 14, no. 5, JPN6017024503, 2010, pages 1064 - 1070, XP009146223, ISSN: 0003827850 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11286463B2 (en) | 2012-03-08 | 2022-03-29 | Advanced ReGen Medical Technologies, LLC | Reprogramming of aged adult stem cells |
JP2019508461A (ja) * | 2016-03-14 | 2019-03-28 | カプリコール,インコーポレイテッド | 眼炎症および目の化学的損傷を細胞外小胞で処置する方法 |
JP7022994B2 (ja) | 2016-03-14 | 2022-02-21 | カプリコール,インコーポレイテッド | 眼炎症および目の化学的損傷を細胞外小胞で処置する方法 |
JP2019513414A (ja) * | 2016-03-24 | 2019-05-30 | ステムラボ,エスエイ | 組織修復のための臍帯血由来エキソソームの使用 |
JP6999575B2 (ja) | 2016-04-29 | 2022-01-18 | アドヴァンスド リジェン メディカル テクノロジーズ,エルエルシー | マイクロrna組成物並びにその作製及び使用方法 |
JP2019514927A (ja) * | 2016-04-29 | 2019-06-06 | アドヴァンスド リジェン メディカル テクノロジーズ,エルエルシー | マイクロrna組成物並びにその作製及び使用方法 |
JP2019526388A (ja) * | 2016-09-09 | 2019-09-19 | アシスタンス パブリック−オピトークス ド パリ(エーピーエイチピー) | 治療用バイオマテリアル |
JP2022180432A (ja) * | 2016-09-09 | 2022-12-06 | コーネル・ユニバーシティー | 硝子体小胞中の核酸、タンパク質及び小分子の送達方法 |
US11759482B2 (en) | 2017-04-19 | 2023-09-19 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
WO2018199231A1 (ja) * | 2017-04-28 | 2018-11-01 | 一丸ファルコス株式会社 | プラセンタ抽出物 |
JP2020518564A (ja) * | 2017-05-05 | 2020-06-25 | カプリコール,インコーポレイテッド | 細胞外小胞を用いた全身移植片対宿主病を治療する方法 |
JP7360704B2 (ja) | 2017-05-05 | 2023-10-13 | カプリコール,インコーポレイテッド | 細胞外小胞を用いた全身移植片対宿主病を治療する方法 |
JP2020529477A (ja) * | 2017-08-04 | 2020-10-08 | シーダーズ—シナイ メディカル センター | がんの治療及び防止のためのカルディオスフィア由来細胞及びその細胞外小胞 |
US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
WO2020209304A1 (ja) * | 2019-04-09 | 2020-10-15 | 孝広 落谷 | 線維化、炎症、及び/又は老化疾患に対する治療薬 |
WO2022202930A1 (ja) * | 2021-03-23 | 2022-09-29 | 国立大学法人京都大学 | 組成物および医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
US9828603B2 (en) | 2017-11-28 |
AU2013302799B2 (en) | 2018-03-01 |
US20180100149A1 (en) | 2018-04-12 |
EP2882445B1 (en) | 2019-04-24 |
US20150203844A1 (en) | 2015-07-23 |
AU2013302799A1 (en) | 2015-02-26 |
EP3563859B1 (en) | 2021-10-13 |
WO2014028493A3 (en) | 2014-04-24 |
US11220687B2 (en) | 2022-01-11 |
CA2881394A1 (en) | 2014-02-20 |
WO2014028493A2 (en) | 2014-02-20 |
JP6726726B2 (ja) | 2020-07-22 |
EP3563859A1 (en) | 2019-11-06 |
US20220119813A1 (en) | 2022-04-21 |
US20200024604A1 (en) | 2020-01-23 |
JP6433896B2 (ja) | 2018-12-05 |
US10457942B2 (en) | 2019-10-29 |
EP2882445A2 (en) | 2015-06-17 |
JP2019038840A (ja) | 2019-03-14 |
EP2882445A4 (en) | 2016-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6726726B2 (ja) | 組織再生のためのエキソソームおよびマイクロリボ核酸 | |
JP7343920B2 (ja) | マトリックス結合ナノベシクルおよびその使用 | |
Rahmati et al. | An overview of current knowledge in biological functions and potential theragnostic applications of exosomes | |
JP2023075258A (ja) | 筋ジストロフィーの処置における心筋球由来細胞およびこのような細胞によって分泌されたエキソソーム | |
KR101835018B1 (ko) | 엑소좀 또는 엑소좀 유래 리보핵산을 포함하는 간섬유증 예방 또는 치료용 조성물 | |
US20220287967A1 (en) | Exosome mimicking nanovesicles making and biological use | |
US20200188440A1 (en) | Methods of inhibiting aging and treating aging-related disorders | |
KR20220002716A (ko) | 간엽 줄기 세포 및 근육 손상 및 근육-관련된 질환의 치료를 위한 이의 용도 | |
JP2022532161A (ja) | 治療活性細胞およびエクソソーム | |
US20200283763A1 (en) | Composition for preventing or treating liver fibrosis, containing exosome or exosome-derived ribonucleic acid | |
JP2023099092A (ja) | カーゴ積載細胞外小胞 | |
Yang et al. | The role of exosomes and exosomal noncoding RNAs from different cell sources in spinal cord injury | |
Hermann et al. | Extracellular vesicles set the stage for brain plasticity and recovery by multimodal signalling | |
US20210238552A1 (en) | Extracellular vesicles loaded with an exogenous molecule | |
Padinharayil et al. | Mesenchymal stem cell-derived exosomes: Characteristics and applications in disease pathology and management | |
da Silva | Genetic engineering of Mesenchymal Stromal Cells to express anti-cancer proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160809 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160809 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170704 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170928 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180104 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180703 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180925 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181016 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181107 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6433896 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |